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Molecular Characterization And Inhibition Of The Myst Acetyltransferase, Hmof
Abstract
Acetylation is one of several post-translational modifications (PTMs) that occurs on histones to regulate
chromatin dynamics and function in DNA transcription, replication, repair, and other DNA-templated
activities, and is carried out by histone acetyltransferases (HATs). Of the multiple HATs that have been
identified to date, the most studied have been classified into five subfamilies based on sequence
homology and substrate acetylation properties. This work is focused on the MYST family (named for
founding members MOZ, YBF2/SAS3, SAS2, and Tip60) of acetyltransferases, and more specifically,
hMOF (human males absent on the first). Despite being the largest, most diverse known family of HATs,
the MYST proteins have not been as well studied as other families. The MYST family has been linked with
a variety of diseases including Alzheimer’s disease, diabetes, and cancer, and some efforts have been
made to develop inhibitors of these proteins. The existing inhibitors for the MYST family, however, are
lacking in either potency, selectivity, or favorable pharmacokinetic properties. The first part of this thesis
will describe our efforts to identify potent, selective hMOF inhibitors using a high throughput screening
campaign. Although this project ultimately uncovered no hMOF inhibitors, it revealed major hurdles that
may be encountered when studying the MYST proteins that will be outlined in detail.
The second part of this thesis will discuss autoacetylation, which is a mechanism of regulation for
acetyltransferases. The MYST family is autoacetylated at an active site lysine residue to facilitate
substrate lysine binding and acetylation, however the mechanism and regulation of this autoacetylation
are not perfectly understood. Here, we will describe a molecular investigation of Lys-274 autoacetylation
of hMOF. These studies revealed that substitutions of Lys-274 are able to bind cofactor but are
destabilized, and are catalytically inactive for histone H4 peptide lysine acetylation, stemming from a
disordering of the residue 274-harboring α2-β7 loop. We also provide evidence that a catalytically inactive
C316S/E350Q mutant and a K268M mutant can still undergo K274 autoacetylation. Together, these
studies point to the critical and specific role of hMOF Lys-274 autoacetylation in hMOF stability and
cognate substrate acetylation and argue that binding of AcCoA to hMOF likely drives Lys-274
autoacetylation for subsequent cognate substrate acetylation.
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ABSTRACT
MOLECULAR CHARACTERIZATION AND INHIBITION OF THE MYST
ACETYLTRANSFERASE, hMOF

Cheryl E. McCullough
Ronen Marmorstein

Acetylation is one of several post-translational modifications (PTMs) that occurs
on histones to regulate chromatin dynamics and function in DNA transcription,
replication, repair, and other DNA-templated activities, and is carried out by histone
acetyltransferases (HATs). Of the multiple HATs that have been identified to date, the
most studied have been classified into five subfamilies based on sequence homology
and substrate acetylation properties. This work is focused on the MYST family (named
for founding members MOZ, YBF2/SAS3, SAS2, and Tip60) of acetyltransferases, and
more specifically, hMOF (human males absent on the first). Despite being the largest,
most diverse known family of HATs, the MYST proteins have not been as well studied as
other families. The MYST family has been linked with a variety of diseases including
Alzheimer’s disease, diabetes, and cancer, and some efforts have been made to
develop inhibitors of these proteins. The existing inhibitors for the MYST family,
however, are lacking in either potency, selectivity, or favorable pharmacokinetic
properties. The first part of this thesis will describe our efforts to identify potent, selective
hMOF inhibitors using a high throughput screening campaign.

Although this project

ultimately uncovered no hMOF inhibitors, it revealed major hurdles that may be

vii
v

encountered when studying the MYST proteins that will be outlined in detail.
The second part of this thesis will discuss autoacetylation, which is a mechanism
of regulation for acetyltransferases. The MYST family is autoacetylated at an active site
lysine residue to facilitate substrate lysine binding and acetylation, however the
mechanism and regulation of this autoacetylation are not perfectly understood. Here, we
will describe a molecular investigation of Lys-274 autoacetylation of hMOF. These
studies revealed that substitutions of Lys-274 are able to bind cofactor but are
destabilized, and are catalytically inactive for histone H4 peptide lysine acetylation,
stemming from a disordering of the residue 274-harboring α2-β7 loop. We also provide
evidence that a catalytically inactive C316S/E350Q mutant and a K268M mutant can still
undergo K274 autoacetylation. Together, these studies point to the critical and specific
role of hMOF Lys-274 autoacetylation in hMOF stability and cognate substrate
acetylation and argue that binding of AcCoA to hMOF likely drives Lys-274
autoacetylation for subsequent cognate substrate acetylation.
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CHAPTER 1
Introduction to the Acetyltransferases

Parts of this chapter were originally published in the Journal of Biological Chemistry,
(McCullough, Cheryl E.; Song, Shufei; Shin, Michael H.; Johnson, F. Brad; Marmorstein, Ronen.
Structural and functional role of acetyltransferase hMOF K274 acetylation. J Biol. Chem. 2016
Aug 26) © the American Society for Biochemistry and Molecular Biology.
Parts of this chapter have been reprinted from Methods in Enzymology, Vol. 573, McCullough,
Cheryl E.; Marmorstein, Ronen. In vitro activity assays for MYST histone acetyltransferases and
adaptation for high-throughput inhibitor screening.pp. 139-160. © Copyright 2016 Elsevier
Inc. Academic Press with permission from Elsevier
Parts of this chapter reprinted (adapted) with permission from McCullough, Cheryl E.;
Marmorstein, Ronen. Molecular basis for histone acetyltransferase regulation by binding partners,
associated domains, and autoacetylation. ACS Chem. Biol. 2016 Mar 18. 11(3):632-642.
Copyright 2016 American Chemical Society."
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1.1 History and Basics of HATs
Acetylation is one of several post-translational modifications (PTMs) that occurs
on histones to regulate chromatin dynamics and function in DNA transcription,
replication, repair, and other DNA-templated activities. The hypothesis that histone
acetylation could regulate gene expression was first proposed by Allfrey and coworkers
in 1964 (Allfrey, Faulkner et al. 1964). However, it was not for another thirty years that
the first histone acetyltransferase, HAT1, was identified by Sternglanz and coworkers
(Kleff, Andrulis et al. 1995) and Gottschling and coworkers(Parthun, Widom et al. 1996).
In 1996, Allis and coworkers isolated the first acetyltransferase, GCN5, from
Tetrahymena, opening the door to the identification of other histone PTMs, the enzymes
that mediated the modifications, and their roles in chromatin regulation (Brownell, Zhou
et al. 1996).
Of the multiple histone acetyltransferases (HATs) that have been identified to
date, the most studied have been classified into five subfamilies based on sequence
homology and substrate acetylation properties: HAT1, GCN5/PCAF, MYST (named for
founding members MOZ, YBF2/SAS3, SAS2, and Tip60), p300/CBP, and Rtt109.
These HATs all share a structurally conserved Acetyl Coenzyme A (AcCoA) binding
core, and within these subfamilies proteins share catalytic mechanisms and structurally
conserved core-flanking regions. Interestingly, despite the structural homology between
many of these proteins, sequence homology is limited for HATs, with the exception of
GCN5/PCAF, and HAT1 which belong to the GCN5-related N-acetyltransferase (GNAT)
superfamily sharing four regions of sequence conservation spanning ~100 amino acids
(Neuwald and Landsman 1997) despite the different substrate specificities between
GCN5/PCAF and HAT1 as reviewed in (Vetting, LP et al. 2005).
2

Histones are not the only proteins that are acetylated.

Through acetylomic

studies, we now know that thousands of proteins are acetylated throughout the cell,
spanning a wide class spectrum, including transcription factors, kinases, ubiquitin
ligases, ribosomal proteins and metabolic enzymes, to mediate a broad range of cellular
functions, including cell cycle control, DNA damage check-points, cytoskeleton
organization, endocytosis and metabolism (Choudhary, Kumar et al. 2009, Smith and
Workman 2009, Spange, Wagner et al. 2009, Zhang, Sprung et al. 2009). While some of
the non-histone acetyltransferases have been identified, such as the α-tubulin
acetyltransferase, αTAT1 (Akella, Wloga et al. 2010, Shida, Cueva et al. 2010) and the
cohesin acetyltransferase, ESCO1 in humans and Eco1 in yeast (Ivanov, Schleiffer et al.
2002, Williams, Garrett-Engele et al. 2003, Hou and Zou 2005), the biologically relevant
enzymes, if any, for many of the other acetylation sites are not known. It should be
noted that several HATs such as p300/CBP have been shown to also acetylate many
non-histone substrates.

3

1.2 HATs and Disease
Given the pervasiveness of acetylation in the cell, it is not surprising that aberrant
protein acetylation or acetyltransferase function has been correlated with multiple human
diseases. While this section will not provide a comprehensive review of all the disease
associations of the HATs, it will touch on some key examples to make a point of the
prevalence of HATs in a number of cancers and other diseases. Specifics regarding the
MYST family of HATs and their disease associations will be discussed later in section
1.5.

1.2.1 p300/ CBP
The p300/CBP family of acetyltransferases has been implicated in a variety of
diseases. Mutations in p300 or CBP can cause Rubenstein-Taybi syndrome, a disease
characterized by facial physical defects and mental retardation (Rubinstein and Taybi
1963, Miller and Rubinstein 1995). The leading diabetes drug, Metformin, was recently
shown to act through p300/CBP inhibition, and heterozygous CBP knockout mice are
lean and exhibit increased insulin sensitivity (He, Sabet et al. 2009). The integration of
HIV-1 virus into the human genome is catalyzed by the viral protein integrase, the
activity of which is also increased by p300-mediated acetylation (Cereseto, Manganaro
et al. 2005). Furthermore, p300 and CBP have been implicated in a variety of cancers.
CBP and p300 null cells formed hematological malignancies (Rebel, Kung et al. 2002).
Additionally, the p300 HAT is mutated in a subset of colorectal and gastric cancers
making it a bona fide tumor suppressor (Muraoka, Konishi et al. 1996). Furthermore,
elevated levels of p300 are often correlated with poor disease prognosis in a variety of
4

cancers including hepatocellular carcinoma (HCC), prostate cancer, cutaneous
squamous cell carcinoma (CSCC), colorectal adenocarcinomas, breast cancer, and nonsmall cell lung carcinoma (Kaypee, Sudarshan et al. 2016). Another study has found that
various types of CBP gene mutations are involved in lung carcinogenesis (Kishimoto,
Kohno et al. 2005).

1.2.2 PCAF/GCN5
The PCAF acetyltransferase has been reported to play a role in multiple disease
states. PCAF was found to be down regulated in esophageal squamous cell carcinoma
(ESCC) (Qin, Fu et al. 2008), in advanced stage ovarian cancers (Sunde, Donninger et
al. 2006) and in intestinal type gastric cancers (ITGC) (Ying, Wang et al. 2010).
Additionally, drug resistance in breast cancer cell lines has been shown to be correlated
with increased PCAF activity (Toth, Boros et al. 2012). Linking aberrant activity to
diabetes, PCAF has also been shown to regulate glucose levels and improve insulin
sensitivity by repressing gluconeogenesis (Sun, Wang et al. 2014). GCN5 has also been
found to be associated with cancer and viral integration as it is over-expressed in nonsmall cell lung cancer (Chen, Wei et al. 2013), and has also been shown to play a role in
HIV-1 viral integration (Terreni, Valentini et al. 2010).

1.2.3 HAT1
Recent studies have linked HAT1 to various diseases, including cancers and
hepatitis. One study has found that HAT1 is over expressed in both primary and
5

metastatic tumors of colorectal cancers (Seiden-Long, Brown et al. 2006). Another study
demonstrated that HAT1 plays role in esophageal carcinoma (EC). In this case, HAT1
was found to be upregulated in primary tumors and expression of HAT1 directly
coorelated with poor EC tumor differentiation (Xue, Hou et al. 2014). Another report
found that a knockdown of HAT1 down regulated hepatitis B DNA in cells, suggesting
that HAT1 may play a role in hepatitis B replication (Wang, Liu et al. 2015).

1.2.4 Rtt109
Unlike the other HATs previously described, Rtt109 is a fungal-specific
acetyltransferase with no known homolog in humans (Wang, Tang et al. 2008).
However, due to its specificity and wide-ranging conservation in fungi, it can be targeted
for anti-fungal therapies in humans. For example, it has been found that deletion of
Rtt109 in the opportunistic pathogen Candida albicans decreases the mortality rate in
infected mice (Lopes da Rosa, Boyartchuk et al. 2010). Rtt109 has also been identified
as a drug target for Pneumocystis pneumonia (PcP), an opportunistic infection caused
by the fungal species Pneumocystis jirovecii (Dahlin, Kottom et al. 2014).

6

1.3 HAT inhibitors
In an attempt to better study the acetyltransferases, and to potentially target them
therapeutically, there have been various attempts to develop acetyltransferase inhibitors.
This section will introduce a few key HAT inhibitors but will not be a comprehensive
review. Rather this section acts as a primer for section 1.6 which will discuss MYST
specific HAT inhibitors in greater depth.
Lys-CoA is a peptide-CoA conjugated bisubstrate inhibitor of p300 developed by
Cole and coworkers. Lys-CoA was both potent with an IC50 of approximately 500 nM and
selective for p300 over PCAF by approximately 200x. However, due to multiple
negatively charged phosphate groups, this inhibitor was not cell permeable (Lau, Kundu
et al. 2000). Later, cell-permeable derivatives of Lys-CoA were developed, but these
compounds showed poorer potency and selectivity for p300 as compared to the parent
compound (Zheng, Balasubramanyam et al. 2005). There are also a number of natural
products that have been shown to inhibit HAT activity including anacardic acid which
inhibits p300 and PCAF with an IC50 of about 7 µM (Balasubramanyam, Swaminathan et
al. 2003) and curcumin, which inhibits p300 with an IC50 of about 25 µM
(Balasubramanyam, Varier et al. 2004). Garcinol, a benzophenone fruit extract, has
been shown to inhibit PCAF and p300 activity with an IC50 value of 6 µM
(Balasubramanyam, Altaf et al. 2004). A monomethylated derivative of garcinol named
LTK14 was later developed, which while maintaining the same IC50 as garcinol, shows
increased specificity towards p300 (Mantelingu, Reddy et al. 2007). Later studies
employed virtual ligand screening to identify the compound C646, a p300 specific, cell
permeable inhibitor, but it is 20x less potent than Lys-CoA (Bowers, Yan et al. 2010).
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1.4 Introduction to the MYST Family
Of the different HAT families that have been characterized to date, the MYST
proteins form the largest and most diverse family (Yang 2004), and are conserved from
yeast to man (Yuan, Rossetto et al. 2012). MYST family proteins have not been as well
studied as some of the other HAT families, yet they play a number of roles in the cell
including gene regulation, DNA repair, and cell cycle homeostasis (Sapountzi and Cote
2011). In addition to histones, MYST family proteins also acetylate a variety of other
proteins including the p53 tumor suppressor (Mellert and McMahon 2009), ORC1 (Iizuka
and Stillman 1999), HIV-1 Tat (Cereseto, Manganaro et al. 2005), and a number of
metabolic regulators (Lin, Lu et al. 2009).
MYST proteins share a structurally conserved AcCoA core binding region with
other HATs, yet they employ several unique structural and catalytic properties within
their conserved HAT domain. The MYST HAT domains contain N- and C-terminal
regions that flank the core binding region that are structurally distinct from other HAT
families. This includes unique N-terminal C2HC zinc finger and C-terminal helix-turnhelix motifs required for their chromatin regulatory activities (Yan, Barlev et al. 2000,
Lafon, Chang et al. 2007).

MYST proteins have been demonstrated to acetylate

cognate substrates through a ping-pong catalytic mechanism, whereby AcCoA binds first
to transfer the acetyl group to an active site cysteine residue to form an acetyl-enzyme
intermediate prior to acetyl-transfer to the cognate lysine substrate.

An active site

glutamate residue which is buried in a hydrophobic pocket to help raise its pKa for
proton extraction is proposed to serve as a key residue for catalysis (Figure 1) (Yan,
Harper et al. 2002). However, another study demonstrates that the yeast Esa1 member
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Figure 1.

Proposed “ping-pong” catalytic mechanism employed by MYST

family acetyltransferases. A glutamate in the active site acts to first deprotonate the
active site cysteine. Next the acetyl group from acetyl CoA is transferred to the
cysteine. The glutamate then protonates the leaving cofactor. The glutamate is then
able to deprotonate the substrate lysine so that the cysteine can transfer the acetyl
group to the lysine. Finally both the glutamate and cysteine react with water to return
to their initial state.
9

of the MYST family, when assembled within a physiologically relevant piccolo NuA4
complex, shows a strong catalytic dependence on the corresponding active site
glutamate residue, but not the active site cysteine residue, suggesting that yeast Esa1
within the piccolo NuA4 complex proceeds through a ternary catalytic mechanism similar
to the other HAT families (Berndsen, Albaugh et al. 2007). More recently, MYST
acetylation of protein substrates was also found to require active site lysine
autoacetylation (Lu, Li et al. 2011, Sun, Guo et al. 2011, Yang, Wu et al. 2012, Yuan,
Rossetto et al. 2012), which will be discussed in further detail in section 1.7.4.
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1.5 MYST Family Implications in Disease
The altered activities of MYST proteins have also been implicated in human
disease. Tip60 is linked to the onset of Alzheimer’s disease (Cao and Sudhof 2001,
Baek, Ohgi et al. 2002, Kinoshita, Whelan et al. 2002, Cao and Sudhof 2004). In 2001 it
was reported that Tip60 formed a transcriptionally active trimeric complex with nuclear
adaptor protein Fe65 and amyloid-β precursor protein (APP), a protein that can be
cleaved to release amyloid-β peptide in Alzheimer’s disease (Cao and Sudhof 2001).
Later it was found that over expression of APP led to upregulation of Fe65 and Tip60 in
transgenic mice (Baek, Ohgi et al. 2002). Furthermore, it was demonstrated that Tip60
could mediate apoptosis induced by the APP cleaved c-terminal fragment (Kinoshita,
Whelan et al. 2002).
MYST family dysregulation has also been implicated in a variety of cancers. An
RNAi screen identified the Tip60 gene as a modulator of p53-dependent function and
senescence avoidance (Berns, Hijmans et al. 2004). Furthermore, Tip60 was
demonstrated to be down-regulated in lung and colon cancer tumor tissues where 7 of
20 colon cancer patients and 8 of 20 lung cancer patients had a statistically significant
down-regulation of Tip60 (Lleonart, Vidal et al. 2006). Contrastingly, Tip60 was
demonstrated to be up-regulated in epithelial tumors of transgenic mice (Hobbs, Wei et
al. 2006). One study has reported that loss of acetylation on the MOF (males absent on
the first) target lysine 16 of histone H4 is common in many human malignancies. In this
study, 25 cancer cell lines including those for leukemia, breast cancer, lung cancer, and
colon cancer were studied using LC-ES/MS as compared to the corresponding normal
cell lines. Every cancer cell line tested revealed a loss in H4K16 acetylation. These
results were then confirmed by isolating histone H4 from the primary tumors of 16
11

lymphomas and 20 colorectal adenocarcinomas, which showed approximately a 40%
decrease in H4K16 acetylation as compared to the normal tissue counterpart cells. This
loss of acetylation occurred as an early event, and progressed with time (Fraga,
Ballestar et al. 2005). Further studies linked MYST proteins to disease by demonstrating
that a recurrent translocation in a subset of acute myeloid leukemias was an in frame
fusion of the HAT domain of the MYST protein MOZ (monocytic leukemia zinc-finger
protein) and CBP (CREB-binding protein) HAT with most of the functional domains
remaining intact. The proposed mechanism of leukaemogenesis for this fusion protein is
aberrant acetylation and transcriptional deregulation of the cAMP and mitogen
responsive signaling pathways (Borrow, Stanton et al. 1996). Later it was also found that
the MOZ-CBP fusion protein could target the AML1 complex to inhibit AML-1 mediated
transcription of hematopoietic genes to induce leukemia (Kitabayashi, Aikawa et al.
2001).
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1.6 MYST Family Inhibitors
1.6.1 Bisubstrate MYST Inhibitors
Because of their connections to disease, there have been efforts to develop
MYST inhibitors. Existing inhibitors, however, are lacking in potency, selectivity, or
favorable pharmacokinetic properties. Wu et al. reported on the development of a series
of bisubstrate CoA-peptide MYST inhibitors based on the various substrate specificities
of ESA1 and Tip60 (Wu, Xie et al. 2009). The specificity of the bisubstrate inhibitors
were tested in comparison to the non-MYST family acetyltransferases, p300 and PCAF,
and the potency of the bisubstrates were tested in comparison to the natural product
HAT inhibitors anacardic acid and curcumin, which inhibit MYST proteins with
approximate IC50 values of 300 µM and 200 µM, respectively. The majority of the MYST
directed bisubstrate inhibitors had low micromolar IC50 values for Tip60 and ESA1.
H4K16CoA was particularly potent against both ESA1 and Tip60, with IC50 values of
approximately 5.5 µM and 17.6 µM respectively, and was thus approximately 20x more
potent than the natural product acetyltransferase inhibitor, anacardic acid. H4K16CoA
however lacked specificity for the MYST enzymes and also inhibited p300 with an IC50 of
approximately 6.6 µM. In fact, most of the bisubstrate inhibitors developed in this study
were more potent against p300 than the targeted MYST protein. This could likely be due
to the fact that MYST enzymes, unlike other acetyltransferases, do not form ternary
complexes for catalysis. Rather, they follow an ordered substrate binding ping-pong
mechanism, which is further supported by the fact that the bisubstrate inhibitor
H4K16CoA was found to be competitive against AcCoA but noncompetitive against
histone substrate when tested with Tip60. In addition to their poor selectivity, the
negatively charged CoA moiety on the bisubstrate inhibitors makes them unlikely to be
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cell permeable and their use may be limited to strictly in vitro studies. However the
authors suggest that their use could be expanded by linking a cell permeable motif to the
compounds (Wu, Xie et al. 2009).

1.6.2 Small Molecule MYST inhibitors
In continuing studies to inhibit MYST family acetyltransferases, virtual screening
was performed to identify small molecule inhibitors of Tip60 using the crystal structure of
ESA1, the yeast homolog of Tip60, as a model (Wu, Wang et al. 2011). The top 76 hits
from the virtual screen were tested for efficacy against Tip60 using in vitro biochemical
assays and two compounds were shown to inhibit Tip60 with IC50 values in the mid
micromolar range. Two further compounds were then selected based on structural
similarity to the initial two hits for a total of four inhibitors resulting from this screen. While
three of the four small molecule inhibitors had better potency than curcumin, the
inhibitors still exhibited poor overall potency and the inhibitors did not exhibit selectivity
between Tip60 and other HAT families. The authors speculate that this could be
because the compounds were found to be competitive with AcCoA and may bind the
AcCoA binding pockets shared by the various families of HATs with comparable affinity
(Wu, Wang et al. 2011).
Because anacardic acid has been shown to inhibit Tip60, albeit with only midmicromolar potency, another study designed a series of analogs of anacardic acid to
determine if they could be developed into more potent, specific inhibitors against the
MYST family. The compounds were evaluated against Tip60, PCAF and p300 in in vitro
biochemical activity assays to test specificity. Overall, the compounds showed a greater
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degree of selectivity towards Tip60 than the two other HATs. The most potent Tip60
anacardic acid analog inhibitors had hydrophobic substitutions at the 6-position in the
salicylate ring, whereas the weakest inhibitors had hydrophilic substitutions at the 6position. Some of the analogs had a phenylethyl substitution at the 6-position, which
improved the lipophillicity of those compounds over the parent anacardic acid
compound, potentially making them improved candidates for lead development. One
analog in particular (referred to as 20 in the referenced manuscript and is now
commercially available by the name MG 149) displayed strong potency against Tip60,
decreasing enzyme activity by 88% at 200 µM, as well as good selectivity with limited
observable inhibition of either p300 or PCAF. This compound was also shown to inhibit
hMOF with a similar potency, demonstrating that it may be a specific inhibitor of MYST
family HATs. Kinetic studies with MG 149 and Tip 60 revealed that the compound is
competitive with AcCoA and noncompetitive with the substrate peptide. The efficacy of
the analogs were also tested on the nuclear extracts of HeLa cells and rat brain tissue
samples. Confirming what had been observed in vitro, the majority of the compounds
displayed a concentration dependent inhibition of histone H4 acetylation. Furthermore,
polar substitutions at the 6-position showed less potency and aliphatic substitutions
showed increased potency in agreement with the studies on the recombinant Tip60
(Ghizzoni, Wu et al. 2012).
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1.7 Autoacetylation
Another mechanism of regulation for acetyltransferases is autoacetylation. Our
lab defines autoacetylation as either a chemical or enzymatic event whereby a protein
can become acetylated in the presence of no other protein except for itself. Currently,
p300, the MYST family of acetyltransferases, Rtt109, and PCAF are all known to be
regulated by acetylation to some degree. Interestingly, despite the prevalence of this
modification amongst acetyltransferases, each HAT subfamily appears to be regulated
by autoacetylation via unique mechanisms (Table 1).
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Table 1. Autoacetylation of HATs
Relevant autoacetylated
Protein

p300

lysine(s)

Functions of acetylation

K1499, K1549, K1554, K1560

•

activates enzyme

•

regulates autoinhibitory loop

•

decreases Km for AcCoA and
substrate peptide

•

activates enzyme

•

decreases Km for substrate
peptide

MOF

Rtt109

K274

•

increases kcat

•

maintains loops conformation

•

conserved throughout MYST
family

K290

•

activates enzyme

•

decreases Km for AcCoA

•

increases kcat

•

2-3 fold increase in catalytic
activity

PCAF

K416, K428, K430, K431, K442

•

increases structural stability

•

localizes PCAF to nucleus

Only autoacetylated lysines with a known effect on enzyme biochemistry have
been listed. MOF has been listed as a representative member of the MYST family.
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1.7.1 Autoacetylation of p300
Within the p300 HAT domain there exists a ~40 residue proteolytically sensitive
lysine-rich loop that can become heavily acetylated to promote catalytic activity. Studies
have found that if this loop of p300 (spanning residues 1520–1560) is deleted the
enzyme becomes constitutively active decreasing the Km for both AcCoA and substrate
peptide rather than increasing the catalytic rate (Thompson, Wang et al. 2004). This loop
is hypothesized to act as an autoinhibitory loop that regulates p300 activity by blocking
substrate binding when unmodified, and exposing the substrate binding region when
acetylated (Thompson, Wang et al. 2004). This model for autoinhibition of the
hypoacetylated loop is consistent with the p300 HAT domain crystal structure, which
shows a highly acidic substrate-binding site that could accommodate a basic
hypoacetylated loop more avidly than a hyperacetylated loop (Figure 2). This
mechanism of autoinhibition was further supported when it was shown that deletion of
this loop in vitro enhanced doxorubicin induced acetylation of the p300 substrate p73
(Thompson, Wang et al. 2004). Along these lines, the effect of this loop deletion on the
ability of p300 to bind the substrate ATF-2 was tested. Not only was the loop
unnecessary for substrate binding, but also a hypoacetylated loop blocked substrate
binding whereas a hyperacetylated loop enhanced substrate binding providing further
evidence that this loop harbors autoinhibitory properties (Karanam, Wang et al. 2007).
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Figure 2. Model for p300 activation by autoacetylation. When the proteolytically
sensitive loop of p300 becomes acetylated, the positive charge is neutralized, and the
substrate binding site of the enzyme becomes accessible. Figure adapted from (Yuan
and Marmorstein 2013)
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1.7.2 Autoacetylation of Rtt109:
Autoacetylation of Rtt109 at lysine 290 is essential for enzyme activation
(Albaugh, Arnold et al. 2011). The acetyl group on this lysine allows it to be inserted into
a hydrophobic pocket of conserved residues (Figure 3) (Lin and Yuan 2008,
Stavropoulos, Nagy et al. 2008, Tang, Meeth et al. 2008). Interestingly, while it seemed
that this residue would thus be important for the thermostability of Rtt109, it was found
that the melting temperature of acetylated Rtt109 did not differ from that of deacetylated
Rtt109, demonstrating that AcK290 likely does not contribute to protein stability
(Albaugh, Arnold et al. 2011). Rather, it was found that acetylation of K290 activated
Rtt109 by increasing the affinity for AcCoA and also increasing the rate of catalytic
turnover (Albaugh, Arnold et al. 2011). The molecular basis by which autoacetylation of
Rtt109 facilitates cognate histone lysine acetylation remains unclear.
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Figure 3. Autoacetylation of Rtt109 K290. The autoacetylated K290 (shown in
green) of Rtt109 in its buried environment. Figure adapted from (Yuan and
Marmorstein 2013)
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1.7.3 Autoacetylation of PCAF
PCAF (p300/CBP-associated factor) was first identified as a p300/CBP binding
protein with histone acetyltransferase activity (Yang, Ogryzko et al. 1996), and further
studies of PCAF demonstrated that PCAF becomes autoacetylated in vitro (Herrera,
Bergel et al. 1997). Moreover, it was shown that the autoacetylation of PCAF occurs in
vivo, and that while PCAF can be acetylated intermolecularly by p300, it also has the
capability to acetylate itself intramolecularly at lysines 416, 428, 430, 441, and 442
(Santos-Rosa, Valls et al. 2003). PCAF displayed greater structural stability and a 2–3
fold increase in catalytic activity when autoacetylated (Santos-Rosa, Valls et al. 2003).
Noting that the five lysines targeted for autoacetylation in PCAF occur at the nuclear
localization signal (NLS) region of PCAF, the effect of autoacetylation on nuclear
localization was investigated. By creating a variety of PCAF constructs and mutants to
mimic the unacetylated state, it was shown that acetylated PCAF localized to the
nucleus whereas unacetylated PCAF localized to the cytoplasm, indicating that
autoacetylation likely plays a role in the regulation of nuclear localization for PCAF
(Blanco-Garcia, Asensio-Juan et al. 2009).

1.7.4 Autoacetylation of MYST Family
A number of recent reports have revealed that autoacetylation of a conserved
lysine residue promotes catalytic activity in the MYST proteins (Lu, Li et al. 2011, Sun,
Guo et al. 2011, Yang, Wu et al. 2012, Yuan, Rossetto et al. 2012). In MOF and Tip60 it
was shown that acetylation of K274 and K327, respectively, upregulated catalytic activity
(Sun, Guo et al. 2011, Yang, Wu et al. 2012). Furthermore, arginine and glutamine
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mutants mimicking lysine and acetylated lysine respectively displayed a >90% loss of
catalytic activity for both enzymes (Yang, Wu et al. 2012, Yuan, Rossetto et al. 2012),
implying that the specific acetyl-lysine modification was required for catalytic activation.
Further biochemical assays also showed that hMOF K274 mutants were defective in H4
binding (Yuan, Rossetto et al. 2012). In a separate study, the autoacetylation of hMOF
was correlated with decreased recruitment of the protein to chromatin in vivo, and
decreased binding to nucleosomes in vitro (Lu, Li et al. 2011). Furthermore, K274
mutants in drosophila MOF display a decreased overall thermostability profile (Kadlec,
Hallacli et al. 2011). K274 makes extensive contacts in the acetylated form that may
contribute to the maintenance of the loop conformation for productive lysine substrate
binding. These include hydrogen bonding of the acetyl carbonyl to Tyr301 and Ser303
and hydrophobic interactions of the acetyl methyl with Phe283 and Phe285 (He, Sabet
et al. 2009, Sun, Guo et al. 2011, Yuan, Rossetto et al. 2012). The crystal structure of
unacetylated hMOF K274, reveals that the lysine is flipped out of the active site by 90° to
both block cognate substrate binding and to form a hydrogen bond with the catalytic
E350 (Figure 4, right), suggesting that that unacetylated lysine residue inhibits cognate
substrate lysine acetylation by both preventing substrate binding and by tying up a key
catalytic residue (Figure 4, left) (Yuan, Rossetto et al. 2012). The mode of K274
acetylation has been proposed to proceed through enzymatic autoacetylation
intramolecularly (in cis), which is consistent with the proximity of acetylated K274 in the
enzyme active site (Sun, Guo et al. 2011, Yuan, Rossetto et al. 2012). However, this
acetylation has also been shown to be independent of the E350 catalytic residue and we
have recently shown that a 19-residue hMOF peptide (261-279) can undergo chemical,
non-enzymatic,

acetylation

at

K274

with
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elevated

AcCoA

concentrations

Figure 4. Close up and schematic of autoacetylation of MYST family
acetyltransferases (MOF used as a representative member.) When unacetylated
K274 forms a hydrogen bond with the catalytic E350. When K274 becomes acetylated
(shown in green) it flips 90° out of the active site and forms a hydrogen bond with
S303, which may permit substrate binding (shown in pink). Overlaying of the
H4K16CoA from the ESA1/H4K16CoA structure (PDB code: 3TO6) reveals that the
substrate would clash with unacetylated K274. Figure adapted from (Yuan and
Marmorstein 2013)
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(Olia, Barker et al. 2015). This finding is consistent with recent studies by us and
others that lysine residues near an appropriately positioned basic residue or basic
patch within proteins have elevated capacities for chemical acetylation (Baeza,
Smallegan et al. 2015, Olia, Barker et al. 2015). For MYST proteins, a conserved lysine
residue is found six residues N-terminal to K274, and we showed that an hMOF peptide
with the corresponding native K268 or K268R mutation can undergo chemical
acetylation while a K268M mutant cannot (Olia, Barker et al. 2015). These findings leave
open the possibility that hMOF K274 autoacetylation may happen non-enzymatically to
‘prime’ the enzyme for cognate substrate acetylation.
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1.8 Dissertation Objectives
This dissertation will focus on my two main projects: the development of a high
throughput assay to screen for small molecule inhibitors of the MYST acetyltransferase,
hMOF, and a characterization study on the catalytic and structural significance of the
autoacetylated lysine in hMOF, Lys 274.
Chapter 2 will mostly cover information published in a chapter for Methods in
Enzymology: Enzymes of Epigenetics entitled “In Vitro Activity Assays for MYST Histone
Acetyltransferases and Adaptation for High-Throughput Screening.” This chapter will
focus more broadly on our high throughput screening campaign, describing methods for
the preparation and biochemical characterization of MYST family acetyltransferases,
including protocols for the preparation of recombinant protein, enzymatic assays for
measuring steady state parameters and binding assays to measure cofactor and
inhibitor binding.

Details will also be provided on adapting these assays for high

throughput screening for small molecule MYST inhibitors. This chapter discusses
hurdles that are likely to be encountered, based on our own experiences, when studying
the MYST proteins.
Chapter 3 will cover the mostly unpublished details of our screening campaign,
discussing the specific results of our screen and the process of hit validation (and lack of
compound validation) upon which Chapter 2 was based. This chapter will detail the
results from each library that was screened, the biochemical assays used to reveal that
compounds were inhibiting hMOF through nuisance behavior rather than specific
binding, and the specific series of events that led to the conclusion of this screening
campaign without any compounds identified for further development. Chapter 3 will also
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provide some reflections on the missteps of the screening campaign and provide future
directions for finding MYST inhibitors.
Chapter 4 will discuss data published in an article in the Journal of Biological
Chemistry entitled “Structural and Functional Role of Acetyltransferase hMOF K274
Autoacetylation.” This chapter details a molecular investigation of K274 autoacetylation
of hMOF. These studies point to the critical and specific role of hMOF K274
autoacetylation in hMOF stability and cognate substrate acetylation and argues that
binding of Ac-CoA to hMOF likely drives K274 autoacetylation for subsequent cognate
substrate acetylation.
Finally, this thesis will conclude with Chapter 5 giving conclusions and future
directions of the work described herein.
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CHAPTER 2
In Vitro Activity Assays for MYST Histone Acetyltransferases and Adaptation for HighThroughput Inhibitor Screening

"Reprinted from Methods in Enzymology, Vol. 573, McCullough, Cheryl E.; Marmorstein, Ronen.
In vitro activity assays for MYST histone acetyltransferases and adaptation for high-throughput
inhibitor screening.pp. 139-160. © Copyright 2016 Elsevier Inc. Academic Press with permission
from Elsevier
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2.1 Preface
This chapter will describe methods for biochemical characterization of MYST
family acetyltransferases, including protocols for enzyme assays for measuring steady
state parameters and binding assays to measure cofactor and inhibitor binding. We also
provide details on adapting these assays for high throughput screening of small
molecule MYST inhibitors.
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2. 2 Preparation of Recombinant MYST Proteins
We generally follow previously described methods for purifying the MYST
proteins (hMOF specifically) (Yuan, Rossetto et al. 2012) but with some modifications.
To study MYST activity in vitro we purify the HAT domain of hMOF, residues 174-449,
with an N-terminal 6xHis tag separated by a TEV protease recognition site. The plasmid
is transformed into E. coli BL21(DE3) codon plus RIL (Stratagene) cells and the protein
is overexpressed in TB media by induction with 1 mM IPTG and grown at 15°C overnight
after the O.D reaches 0.8-1.5. The cells are harvested and lysed by sonication in lysis
buffer containing 50 mM HEPES (pH 7.5), 0.5 M NaCl, 2 mM β-mercaptoethanol, 5 mM
imidazole, 5% glycerol, 0.1% CHAPS and 0.1 mM phenylmethylsulfonyl fluoride. The
lysate is cleared by centrifugation at 28,000g for 30 min at 4 °C. The supernatant is then
loaded onto Nickel charged NTA resin (Qiagen) that has been equilibrated with lysis
buffer. The resin is then washed with 10 column volumes of lysis buffer containing 25
mM imidazole and then eluted with lysis buffer containing 250 mM imidazole buffer in 10
mL fractions. Because we found that the 6xHis tag does not interfere with hMOF activity
or crystallization, we do not cleave the tag. Instead we proceed directly from the affinity
column to size exclusion chromatography, skipping ion exchange gel chromatography
due to hMOF sensitivity to low salt conditions. The hMOF is concentrated and injected
onto an FPLC using a HiLoad Superdex 75 16/60 gel filtration column using a gel
filtration buffer composed of 20 mM HEPES (pH 7.5), 0.5 M NaCl. We then concentrate
the hMOF protein to ~50 µM, aliquot to ~10 µL, flash freeze using liquid nitrogen, and
store at -80°C. Once we thaw an aliquot of hMOF we discard the remainder of that
aliquot as multiple flash freezings has a negative impact on enzymatic activity. In our
experience hMOF expresses and purifies fairly well, and 1L of cells will yield
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approximately 5mg of protein. In the case of hMOZ and yESA1, we found that the
proteins express better in LB rather than TB, but still express about 10x less protein than
hMOF. Both MOZ and ESA1 tolerate ion-exchange well, and achieve a higher level of
activity if sizing buffer/storage buffer is at a low pH and contains reducing agent. We use
20 mM sodium citrate pH 5.5, 100 mM NaCl, and 1 mM DTT.
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2.3 Kinetic Analysis
2.3.1 Primer on Steady State Kinetic Analysis
The steady state kinetic parameters of a protein include the Michaelis constant
(Km), which is the concentration where the reaction rate of the enzyme is at one-half of
its maximal velocity (Vmax) and is related to the affinity of an enzyme for its substrate,
and the catalytic constant (kcat), which is the rate that an enzyme turns over its
substrates (Figure 5).
To determine the kinetic parameters for a given enzyme, very carefully
conducted activity assays must be performed. The basic steps to follow to determine
these parameters for a bisubstrate system such as the MYST family are to hold one
substrate at a saturating concentration (~10x Km) while the other substrate is varied.
About half of the concentrations of the varied substrate should be below Km and the
other half above Km. Generally a minimum of eight concentrations should be used
(Brooks, Geeganage et al. 2004). Results are then graphed as substrate concentrations
versus reaction rate to obtain a Michaelis-Menten curve.
A kinetics reaction must be run under steady state conditions, meaning that the
reaction is occurring at a linear rate and less than 10% of the substrate is consumed.
These parameters ensure that substrate concentration ([S]) can be assumed to remain
constant for a given point. To find steady state conditions a reaction progress curve
should be obtained before starting kinetic assays. Additionally, enzyme concentration
must be significantly lower than substrate concentration (generally at least 100x lower),
this allows for enzyme concentration to be equated to zero and exclude from the
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Figure 5. Michaelis-Menten equation, kcat equation and graphical
representation of the Michaelis-Menten equation where ν= reaction rate, [S] =
substrate concentration, Vmax= maximum reaction velocity, Km
constant, and [ET] = total enzyme concentration.
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=

Michaelis

Michaelis-Menten equation. Furthermore, to obtain kcat from a graph of Michaelis-Menten
data, assay output signal must be converted to reaction rate. To do so, a standard curve
should be generated so that output can be converted to a known amount of substrate
conversion. For example, in our radioactivity assays the read out is in CPM (counts per
minute) based on how much

14

C-acetyl is transferred from the acetyl CoA to H4. To

generate our standard curve we measure a known number of moles of

14

C- acetyl CoA

so that CPM can be related to molar transfer of the acetyl group in a linear equation.
That value is then divided by reaction volume to obtain a reaction rate with units of Ms-1.

2.3.2 Specific Kinetic Properties of MYST Acetyltransferases
The MYST family of acetyltransferases exhibit high substrate Km values. For
example, the Km for the yESA1 HAT domain is ~920 µM for histone H3 (Yan, Barlev et
al. 2000). This high Km for the substrate peptide causes saturating conditions to be
extremely high, which can cause complications for kinetic assays. For example in the
case of the yESA1, 9.2 mM of H3 would be 10x Km, and thus saturating. To
accommodate this MYST family characteristic, we have mainly used radioactivity based
assays to measure enzyme activity. Radioactive read outs tend to be quite sensitive,
and are not typically limited by binding capacities. For example if we require the
attachment of the peptide substrate to a bead for a fluorescence based assay, the
binding capacity of the bead might be less than saturating for the peptide and we might
then not be able to achieve maximum velocity (Vmax). Furthermore, when using a
synthetic peptide as the substrate, using such a high concentration may lead to
trifluoroacetic acid (TFA) contamination that could destabilize the enzyme. According to
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Genscript’s website, synthetic peptides may contain 10-45% TFA salt. This amount of
TFA could be damaging to the enzyme of interest, leading to a much lower Vmax in
assays where the peptide is the saturating component, or a decrease in activity as
peptide concentration increases. To avoid this issue, we have used slightly less than 10x
Km as an assumed saturating condition.

2.3.3 Controlling for Chemical Acetylation
Another hurdle that we have encountered in our lab is chemical acetylation of
substrates. Because the acetyl group on acetyl CoA is a fairly labile bond it is possible
for the acetyl transfer to occur in the absence of enzyme, especially with high
concentrations of acetyl CoA in the presence of basic peptides. To control for this
background chemical acetylation, it is imperative to include a control experiment that
contains substrate and acetyl CoA but no enzyme. This can be especially important
when testing very low activity levels such as when studying catalytic mutants. The
chemical acetylation should then be subtracted from assay readouts to obtain a more
accurate value for enzyme activity. For an example see (Figure 6).

2.3.4 Kinetic Assay Using Radioactive Acetyl-CoA
To perform kinetic experiments using a radioactivity-based assay we first mix
hMOF at 50 nM with H4 peptide in PCR tubes in a buffer containing 40 mM Tris (pH
8.0), 100 mM NaCl, 800 µM Cys, and 7.5µM BSA. Depending on which substrate is
tested, H4 will either be at varied concentrations or saturating. We begin the
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Figure 6. Progress curve showing the enzymatic activity of the hMOF174-449
K274M mutant over time as compared to a chemical acetylation control,
which contains only the substrate and acetyl-CoA, but no enzyme. The
acetylation that occurs in the presence of the mutant enzyme is just slightly greater
than the chemical acetylation observed in the absence of enzyme, indicating that
this mutant has lost much of its catalytic activity. Note, however, that the activity
levels of the mutant enzyme could be misleading without the chemical acetylation
control.
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assay by

adding

14

C-acetyl CoA (which will also be varied or saturating depending on

which substrate is being examined) in a final volume of 50 µL. Because these assays
are so sensitive, and we want each experiment to run for exactly the same amount of
time, we space out each reaction by 30 seconds (that is, begin reaction one at time 0:00,
two at 0:30, three at 1:00 etc.). We allow the reaction to proceed for eight minutes,
which we have previously determined to be within the linear range for the enzyme. To
stop the reaction, we spot 20 µL each of the reaction onto two P81 filter papers, which
will bind the positively charged H4 peptide. This step, again, is done in 30-second
intervals so that each reaction proceeds for exactly eight minutes (that is, spot reaction
one at time 8:00, two at 8:30, three at 9:00 etc.). The filter papers are then washed 3x in
20 mM HEPES (pH 7.5). Because water is insoluble in some scintillation fluids and might
interfere with signal readout, we dip each filter paper in acetone and lay each one out to
dry on a paper towel. We then put each filter paper in a scintillation vial, add scintillation
fluid and read our results on a scintillation counter where CPM will correlate with the
amount of
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C-acetyl that has been transferred from the acetyl CoA to the H4 peptide

and thus, enzyme activity. We can then use this data to prepare Michaelis-Menten
curves for the enzyme (Figure 7).
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Figure 7. Michaelis-Menten curves and calculated steady state parameters
for hMOF174-449. Note that these values vary somewhat from the aforementioned
Km values for hMOF of 50 µM and 400 µM for acetyl CoA and H4 peptide,
respectively, likely due to the difference in enzyme preparation and buffer
conditions. To calculate kcat for this data, Vmax was divided by the total enzyme
concentration of 50nM
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2.4 Thermofluor Assay to Investigate Cofactor and Inhibitor Binding
A thermofluor assay measures the melting temperature of a protein (Pantoliano,
Rhind et al. 2000). If the protein is stabilized by a cofactor or ligand it will have a higher
melting temperature. For example, Apo hMOF HAT domain has a Tm of about 37°C,
however, upon addition of 100 µM CoA, acetyl CoA, or acetonyl CoA the Tm increases to
approximately 47 °C, 50 °C and 52 °C, respectively; interestingly, however, we do not
observe a strong thermal shift of hMOF in the presence of H4 peptide (Figure 8). The
thermofluor assay uses SYPRO® Orange, a dye that fluoresces in a hydrophobic
environment. Thus if SYPRO® Orange is present as a protein is melting it will bind the
exposed hydrophobic patches and will fluoresce with increasing intensity as a protein
unfolds. This data can then be plotted to produce a melting curve.
There are some caveats to this assay. Firstly, because of the nature of SYPRO®
Orange fluorescence in a hydrophobic environment, detergent in the buffer can interfere
with signal. In our experience, baseline fluorescence of SYPRO® Orange in the
presence of detergent (0.05% Triton-X) is significantly increased, and completely masks
any melting data from the protein. Decreasing to 0.01% Triton X shows some
improvement but still complicates the melting curve of the protein. It is also possible that
the detergent may directly affect protein unfolding properties. If detergent is absolutely
required, then other dye options would need to be explored to employ this assay.
Additionally, if another protein is present in the sample (a contaminant or BSA, for
example) that protein will melt also, producing its own melting curve in tandem with the
protein of interest and thus complicating the data.
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Figure 8. Thermofluor assay as a readout of hMOF ligand binding. Data for
apo hMOF, and hMOF in the presence of 1 mM H4 peptide, and 100 µM CoA,
acetyl CoA, and acetonyl CoA , respectively. Tm is the inflection point for each
curve: ~37°C for apo hMOF, ~47°C for hMOF with CoA, ~50°C for hMOF with
acetyl CoA, ~52°C for hMOF with acetonyl CoA, and ~38°C for hMOF with H4
peptide.
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2.5 Inhibitor Screening
2.5.1 General Considerations
When beginning a screening campaign, one should consider what assay is going
to be most appropriate for the system being tested and what buffer conditions are
appropriate for that assay. Typically, an additive of some kind will be required to
terminate all of the reactions in a high throughput screen simultaneously; for our assays
we have used 3.7% HCl for this purpose. Also, a control inhibitor is often required to
monitor screening quality statistics. Acetonyl-CoA is a non-hydrolyzable acetyl CoA
analog that has served us as a control inhibitor against MYST proteins. An orthogonal
secondary assay must also be planned to counter screen any hits from the primary
assay to eliminate any false positives that may have interfered with the detection system
of the primary assay. There are also a few standard statistics for HTS that should be
performed before screening compound libraries. One important validation statistic is the
Z-factor, a parameter which measures the screening window of an assay to assess
assay quality (Figure 9) (Zhang, Chung et al. 1999).
The Z-factor can be any value from 0 to 1 where assay quality increases with
increasing Z-factor, which would indicate a large signal window with low signal
variability. To obtain a Z-factor a control plate should be run in the assay where half of
the reactions are a control for positive signal (enzyme with no inhibitor present/ DMSO
only) and the other half of the reactions are controls for background signal (either
containing no enzyme, a catalytically dead mutant of the enzyme, or WT enzyme plus a
saturating amount of control inhibitor, depending on what is available). The means and
standard deviations of the results can then be calculated and put into the equation
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Figure 9. Equation and sample data for determining assay Z-factor. Z’= Zfactor, σs = standard deviation of the positive signal, σb= standard deviation of the
background signal, µs =mean of the positive signal, and µb =mean of the
background signal. Each point in the graph represents the readout for a single
reaction within a 384 well plate.
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shown in Figure 9 to calculate Z-factor. Generally the minimum acceptable Z-factor
value is 0.5, with higher values being more desirable (Zhang, Chung et al. 1999).
In general, when screening for inhibitors each substrate concentration should be
set at Km within a reaction. This allows the assay to be sensitive to competitive inhibitors
while maintaining robust signal (Williams and Scott 2009). However, this can pose a
problem for MYST family proteins, which tend to have a very high Km for their substrates.
It must be determined if enough of the substrate can be obtained to perform an entire
screening campaign, which often involves a minimum of thousands of reactions.
Furthermore, if the assay requires immobilization of the substrate, then the binding
surface must have a high enough capacity to reach substrate Km. It may be reasonable
to use less than Km of the substrate if the Km is too high to reasonably achieve in the
screen. However in this case, it is important to consider that lowering the substrate
concentration will slow the reaction rate. This may mean that the reaction will have to be
run for a longer amount of time to obtain a detectable signal to noise ratio. In this case, it
is important that the enzyme be stable enough to survive the duration of the assay.
Additionally, lowering the concentration of one substrate in a bisubstrate system causes
the screen to have a greater bias for finding inhibitors that are competitive with that
substrate as it could then be easier to compete off of the enzyme.

2.5.2 Buffer Considerations
It is important to remember that when transitioning from low throughput to high
throughput assays there will potentially be a transition to more forms of solution transfer
which may translate into a greater variety of contact surfaces for the enzyme/ reaction
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mixture (tubing, transfer pins, etc.). In our experience working with the MYST protein
hMOF, we have found that while we have had limited difficulty with protein stickiness in
low throughput, we lose a significant portion of the protein through the course of transfer
steps. To alleviate the effects of a much lower signal than expected when transitioning
from low throughput to high throughput we tested the addition of bovine serum albumin
(BSA) to our assay buffer, finding that it increased our signal by about 5 times.
Cysteine reactive compounds can lead to a high number of false hits in a
screening campaign. In the case of MYST HATs, which have been demonstrated to
employ an active site cysteine for acetyltransferase activity (Yan, Harper et al. 2002),
this can be a particular problem. It may be appropriate to add some amount of reducing
agent to the reaction buffer to limit the amount of inhibition due to compounds reacting
with the active site cysteine. This however can lead to more problems as it has been
shown that redox cycling, or production of peroxide caused by strong reducing agent
interactions with some compounds, can also lead to a high false hit rate (Johnston,
Soares et al. 2008). To circumvent this issue, we have included in some of our assays
free cysteine in an attempt to outcompete cysteine reactive compounds.
Small amounts of non-ionic detergent can also help to decrease a false hit rate
(Feng, Simeonov et al. 2007). This is especially true when screening MYST family
acetyltransferases where screening at a higher compound concentration may lead to
colloidal aggregation, which will be discussed in more detail in section 2.5.6.
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2.5.3 Assays
In the case of the MYST acetyltransferases, we have developed a radioactivity
based assay and an ELISA assay to use in high throughput. We have also developed a
thermofluor assay to be used as a secondary orthogonal assay in low throughput.

2.5.3.1 Radioactivity Based Assay
Because of the sensitivity and robustness of radioactivity assays, we decided to
adapt the radioactivity based P81 filter paper assay discussed in section 2.3.4 to be
used in high throughput as a primary assay. The assay is performed by dispensing
hMOF (or inactive mutant hMOF E350Q as a negative control) into each well of a 384
well plate followed by the addition of compound and then an H4 peptide/
solution to final concentrations of 50 nM hMOF, 50 µM

14
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C-acetyl CoA

C- acetyl CoA, and 400 µM H4

peptide (both substrates are used at ~Km) in 40 mM Tris (pH 8.0), 100 mM NaCl, 800 µM
Cys, and 7.5 µM BSA. The reaction is allowed to proceed for 1 hour (allowing for 4060% substrate conversion, not performed at steady state) and then 3.7% HCl is added to
each well to stop the reaction. The reaction is then transferred from the 384 well plate to
four 96 well p81 paper embedded mesh bottom plates. A vacuum manifold is used to
pull excess liquid from the wells. Next, each well is washed with 10 mM HEPES (pH
7.5), followed by addition of acetone, which is also vacuumed off. The plate bottoms are
then sealed and scintillation fluid is added to each well. The plates are then sealed and
read on a TopCount plate reader. The Z-factor for this assay has remained >0.6 for all
optimized trials and we have confirmed the ability of the assay to detect inhibition by
acetonyl CoA.
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2.5.3.2 ELISA Assay
We also developed an ELISA assay, which is performed in automation by first
binding H4-GST to a 384-well glutathione coated plate. We have found that hMOF
acetylates H4-GST almost as well as H4 peptide, whereas GST-H4 barely becomes
acetylated at all. 50 nM enzyme, followed by test compounds are added to the plate
followed by 50 µM acetyl CoA. The reaction is allowed to react for 3 hours to obtain a
suitable signal window. Primary anti-H4AcK antibody is added and allowed to bind for
30 minutes. Next, the secondary antibody conjugated to horseradish peroxidase (HRP)
is added and allowed to bind for 30 minutes. Chemiluminescent substrate is added and
is oxidized by HRP to produce light that can be detected on a plate reader. The plate is
washed between each step. The Z-factor has remained reproducibly above 0.6. This
assay provides a good example of how requiring a binding surface may limit how much
substrate can be included in the assay, thus slowing reaction time. In the case of this
assay, because screening could take multiple hours, the stability of the assay was tested
as a function of time.
Another important aspect of this assay to note is that not all primary antibodies
developed to recognize the acetylated substrate perform equally well. In the case of this
assay, multiple antibodies were characterized via a dot blot as well as screening within
the assay to ensure we could achieve the highest signal to noise ratio with the best
performing antibody. In our experience, Histone H4 tetra-acetyl antibody (pAb) (Cat#
39179, 39228), and Histone H4ac (pan-acetyl) antibody (pAb) (Cat# 39243, 39244) from
Active Motif have performed relatively well in our assay giving signal windows of
approximately 10x and 4x, respectively.
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2.5.3.3 Thermofluor Binding Assay
We have taken advantage of the thermofluor assay as a secondary orthogonal
screen to perform in low throughput to validate compounds identified in the primary
assay. We have also begun efforts to translate this assay from low throughput to high
throughput for fragment screening. We currently perform the high throughput assay by
adding 15 µL of 10 µM hMOF in 20 mM HEPES pH 7.5, 300 mM NaCl to each well,
followed by 1 µL of 20 mM fragment compound to a final concentration of 1 mM
compound (or 100 µM CoA as a positive control). After allowing the compounds to sit
with the protein for 30 minutes, 4 µL of a 1:300 dilution of 5000x SYPRO® Orange dye is
added to each well. The plate is then sealed and read on a real-time qPCR instrument.
For this assay, we have had some difficulty with deviations in control Tm and obtaining
quality screening statistics. Further optimization will be required to determine if this
assay will be suitable for high-throughput screening of MYST proteins.

2.5.4 Eliminating Promiscuous Inhibitors
After completing this screening campaign, it was important to focus on the
highest quality hits that had the potential to be developed into probes or therapeutics. In
general, a good inhibitor should display reproducible dose-dependent inhibition, have a
Hill slope of approximately 1.0, bind reversibly to the protein (although covalent inhibitors
can be beneficial under certain circumstances they will not be discussed here), and also
be selective for the protein of interest. When a compound identified through screening
does not meet these criteria, it becomes important to scrutinize it carefully to identify and
eliminate compounds that are disrupting enzymatic activity through nonspecific
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interactions. For example, through the course of this HTS campaign, hMOF was found to
be particularly sensitive towards cysteine reactive compounds, mercury containing
compounds, and copper containing compounds. As mentioned earlier, MYST proteins
have an active site cysteine responsible for acetyl transfer, thus cysteine reactive
compounds may nonspecifically form disulfide bonds to inhibit the protein. Similarly,
mercury-containing compounds are also able to interact nonspecifically with the active
site cysteine. Additionally, in our experience, copper-containing compounds are
especially active against the hMOF. We hypothesize that this occurs because either the
copper interferes with the active site cysteine, or otherwise may be displacing the zinc in
the zinc finger or both. These three types of compounds are poor candidates for further
optimization.

2.5.5 PAINS
Pan-assay interference compounds (PAINS) are a class of compounds that
mimic genuine inhibitors by interfering with assay readouts or undergoing nonspecific
reactions with proteins. About half of PAINS known today fall into just 16 structural
categories (Baell and Walters 2014), and learning these structures can save a lot of time
and effort. However, because about half of PAINS do not fit into these categories it is
also prudent to check the literature for other reports of a selected compound hitting
unrelated proteins as this could be a red flag (Baell and Walters 2014).
In our experience with hMOF screening, it is especially important to verify the
identity and purity of the identified hits in the library. Compounds within a library can
break down over time into reactive products (Baell and Walters 2014). Through the
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course of our assays, we have found that hMOF had numerous hits where mass spec
revealed a plethora of compounds were present in the sample when there should have
only have been one. This leads us to believe that MYST proteins may be particularly
sensitive to these sorts of reactive breakdown products.
Testing for the reversibility of a compound can be a fairly straightforward way to
determine if it is interacting with the protein of interest through desirable interactions. If a
compound is specifically binding a region of a protein in a dose-dependent manner, then
the enzyme should regain activity when the compound is diluted (Copeland 2005).
Briefly, to perform this experiment in the context of the MYST protein hMOF, 5 µM
enzyme is first incubated with 10 x IC50 of a compound for ~30 minutes. The solution is
then diluted 100 x such that the enzyme concentration is at 50 nM and the compound is
at 0.1 x IC50, where little to no activity should be expected from an inhibitor. A reaction is
then started by adding H4 peptide and acetyl CoA at Km and time points are taken every
five minutes for an hour. As a positive control for reversibility, we measure enzyme
activity with no inhibitor added (DMSO control) as well as enzyme activity with the
reversible inhibitor acetonyl CoA. As a negative control for reversibility, we used
merbromin, a mercury-containing compound containing free mercury that interacts with
the active site cysteine. If a compound reversibly binds to the enzyme then the activity
of the enzyme should increase with time aligning with the positive controls, and if a
compound is irreversible, the enzyme will remain inhibited and little activity will be seen
over time, aligning with the negative control (Figure 10). Compounds that are found to
be irreversible inhibitors may be nonspecifically modifying the protein of interest and are
much less likely to serve as good candidates for optimization.
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Figure 10. Sample data for an enzyme recovery assay with a MYST protein.
Note that both of the test compounds display irreversible inhibition, as they inhibit
enzyme activity after dilution, aligning with the control irreversible inhibitor
merbromin, a mercury containing compound that interacts with the active site
cysteine. Also note that acetonyl CoA, a reversible inhibitor, aligns very closely to
the DMSO control.
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2.5.6 Colloidal Aggregators
Colloidal aggregators are compounds that aggregate and sequester a protein to
limit its activity (McGovern, Helfand et al. 2003). This can be a particular problem when
screening MYST proteins as compounds tend to be screened at higher inhibitor
concentrations (low micromolar range) where they can have a higher tendency to
aggregate. In general, if a compound is reversibly interacting with an enzyme in a 1:1
stoichiometry then the Hill slope for that compound with the enzyme should be ~1 (Feng,
Simeonov et al. 2007), and if the Hill slope is higher than 1, this may indicate that the
compound is acting through colloidal aggregate inhibition. Colloidal aggregates can be
solubilized by the addition of small amounts of non ionic detergents (~0.01% Triton-X)
(McGovern, Helfand et al. 2003). If running an activity assay in the presence of
detergent causes the inhibitory activity of a compound to be lost or significantly
decreased, this may be a sign that the compound is acting via aggregation rather than
by a specific interaction. To avoid initial identification of colloidal aggregators in a
primary screen it can be helpful to include small amounts of non-ionic detergent in the
assay buffer. However, if detergent interferes with the assay readout of the primary
screen, it is important to then include detergent in secondary screens to eliminate
compounds acting through colloidal aggregation.
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2.6 Conclusions
The MYST family proteins remain one of the more understudied families of the
acetyltransferases. This is likely, at least in part, due to their weak affinity for their
substrates, which can make them especially challenging to study. Furthermore, the
MYST proteins appear to be only weakly inhibited by validated inhibitors, and
significantly sensitive to nonspecific inhibitors further complicating efforts to further probe
their activity and find new inhibitors.
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CHAPTER 3
High Throughput Screening Results
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3.1 Introduction
3.1.1 Preface
While the previous chapter sought to provide a general description of procedures
and considerations from the HTS campaign, this chapter will delve into the specific
results from the HTS including the compounds we investigated, how we discovered their
shortcomings, and the hurdles we encountered. This chapter focuses on the results
obtained from screening, rather than development or optimization steps, though some
results that led to changes of assay conditions will be noted. This chapter provides the
context upon which the previous chapter was constructed, and provides the specific data
on which the method optimizations and considerations were based.

3.1.2 Overview
This chapter will describe the screening of over 150,000 small molecules and a
variety of natural products from six different libraries using two different high throughput
screening assays in a search for inhibitors of the MYST family acetyltransferase, hMOF.
The first assay employed was an ELISA based assay described in section 2.5.3.2.
Briefly this assay was performed in 384-well glutathione coated plates using a H4-GST
substrate, a primary antibody that recognized H4 acetyl-lysine, and a luminescent readout. Chronologically, we began our screening campaign with this assay as our primary
assay, and successfully screened three libraries including the Spectrum Collection, the
NIH Clinical Collection, and the ChemDiv Library.

However, due to a number of

technical issues including high false hit rate, and discontinuation of the glutathione plates
with which we had optimized the assay, we switched our primary assay from the ELISA
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to a radioactivity assay. The high throughput radioactivity assay is described in section
2.5.3.1. Briefly, this assay was performed using

14

C-acetyl-CoA and an H4 peptide

substrate. The reaction was carried out in 384-well plates before being transferred using
automation to 96 well plates embedded with the H4-binding P81 filter paper.
The results in this chapter will be grouped into the stages of hit validation, even
though chronologically, the results were validated following each library screening as a
method of quality control. Therefore, the libraries that were screened with the ELISA
assay had their initial results rescreened in the ELISA assay, and the libraries that were
screened using the radioactive assay, had their initial hits rescreened in the radioactive
assay. Because of nuances such as these, the results and discussion in this chapter are
grouped in to one section to allow for thorough explanations and data clarification.

3.1.3 Definitions
Hit/Active Compound: a compound/sample well in the screen that inhibits
hMOF by three standard deviations below the mean signal.
Matrix: A library that is “matrixed” means that each sample well has a mixture of
several compounds (generally 5-10) and each unique compound appears in the screen
twice, but shares a well with two completely different sets of compounds. The data in a
matrixed library can be deconvoluted by finding which compound is shared between two
hit wells. Matrixing a library improves efficiency by increasing the number of compounds
that can be screened over a period of time.
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3.2 Materials and Methods
3.2.1 Protein Expression, Purification, and Quality Control
To purify hMOF, we followed previously described methods for purifying the
MYST proteins (Yuan, Rossetto et al. 2012) but with some modifications, which have
been specifically outlined in section 2.2 of this thesis. To ensure reproducibility of results
throughout the screening campaign each new preparation of the hMOF protein was
tested side by side with previous preparations using low throughput
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C-acetyl CoA

based activity assays prior to use in a screen.
The recombinant histone H4 (residues 1-34) with a C-terminal GST tag in
pET28A was expressed and purified as follows. The plasmid was transformed into E.
coli BL21(DE3) codon plus RIL (Stratagene) cells and the protein was overexpressed in
LB media, induced with 1mM IPTG at OD 0.5-0.8, and grown at 18°C overnight. The
cells were harvested and lysed by sonication in lysis buffer (100 mM Tris (pH 8.0), 0.5 M
NaCl, 0.2mM EDTA, 1% Triton-X, 5 mM DTT, and 5% glycerol) with 1 mM
phenylmethylsulfonyl fluoride followed by centrifugation at 28,000g for 30 min at 4 °C.
The lysate supernatant was then incubated with GST resin (Gold Bio) equilibrated with
lysis buffer for 3 hr at 4°C. The resin was washed with 10 column volumes of lysis buffer.
The protein was eluted with lysis buffer containing 25 mM reduced glutathione in 10 mL
fractions. The eluent was dialyzed overnight at 4°C to eliminate free glutathione. Then
the H4-GST protein was concentrated, aliquotted, flash frozen and stored at -80 °C.
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3.2.2 High Throughput Assays
Two different high throughput screens (HTS) were employed during the course of
this screening campaign. The first assay is the ELISA based HTS, described in detail in
section 2.5.3.2. The second assay is the radioactivity based assay, described in detail in
section 2.5.3.1.

3.2.3 Low Throughput Assays
3.2.3.1 Radioactivity Based Assay
The low throughput radioactivity based assay was performed using the same
parameters as the HTS radioactivity assay, but with slightly different protocols. Briefly,
for the low throughput radioactivity assay, hMOF was mixed at 50 nM final concentration
with a reaction mixture containing 50 µM
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C- acetyl CoA, and 400 µM H4 peptide in the

presence or absence of a test compound. Reaction components were diluted in a buffer
containing 40 mM Tris (pH 8.0), 100 mM NaCl, 800 µM Cys, and 7.5 µM BSA to a final
volume of 50 µL. The reaction was allowed to proceed for 1 hour to allow for 40-60%
substrate conversion and then stopped by spotting 20 µL each of the reaction onto two
P81 filter papers. The filter papers were then washed 3x in 20 mM HEPES (pH 7.5),
dipped in acetone and dried. Each filter paper was put into a scintillation vial with
scintillation fluid and read on a scintillation counter.
3.2.3.2 Thermofluor Assay
The low throughput thermofluor assay employing the environment sensitive dye,
Sypro Orange, is described in sections 2.4 and 4.2.3.
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3.2.4 Screening Libraries
3.2.4.1 Spectrum Collection
The Spectrum Collection from MicroSource Discovery Systems, Inc. is a
collection of 2560 compounds comprised of 4 smaller screens: the US Drug Collection,
the International Drug Collection, the Natural Products Collection, and the Discover
Collection. Thus, the Spectrum Collection contains a variety of compounds including
those that have reached clinical trials in the United States, or have been marketed
abroad in Europe or Asia, as well as purified natural product compounds from animals,
plants, microbes, and bioactive compounds identified in peer-review publications that
have never been developed into drugs. This library was screened in both the ELISA
formatted HTS and the radioactive p81 filter paper based HTS using a final compound
concentration of 25 µM.
3.2.4.2 NIH Clinical Collection
The NIH Clinical Collection (NCC) is a compound library assembled by the
Molecular Roadmap Initiative at the NIH and is comprised of ~450 small molecules that
have been used in clinical trials. Because this library contains so few compounds it was
combined with the Spectrum Collection for our screens. This library was screened in
both the ELISA formatted HTS and the radioactive HTS using a final compound
concentration of 25 µM.
3.2.4.3 ChemDiv Library
The ChemDiv Library is composed of 30,000 compounds from The Discovery
Chemistry (DS) set and 20,000 compounds from the Target Specific Chemistry (TS) set
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from ChemDiv, Inc. Together these compounds represent drug-like small molecules,
some of which have been shown to have specificity for certain targets including Gcoupled protein receptors, kinases, ion channels, proteases, and nuclear hormone
receptors. The ChemDiv library was matrixed with five different compounds per sample
well with each compound being present in two wells, and was screened with the ELISA
HTS assay using a final concentration of 20 µM per compound, and thus 100 µM total
compound per well.

3.2.4.4 The Maybridge “Hitfinder” Library
The Hitfinder Library from Maybridge is comprised of 14,400 compounds. These
compounds all follow the Lipinski rules for drug-likeness, meaning that they have clogP
≤ 5, hydrogen bond acceptors ≤10, hydrogen bond donors ≤5, and molecular weight ≤
500. Furthermore, to minimize false hits, the compounds in the Hitfinder Library have
been selected to be non-reactive. This library was screened using the radioactivity p81
filter paper based HTS with a 25 µM final compound concentration.

3.2.4.5 The Natural Product Discovery Institute Library
The Natural Product Discovery Institute (NPDI) collection consists of plant,
fungal, and actinomycetous extracts, where multiple rounds of screening and
fractionation are performed in collaboration with scientists at NPDI. After each round of
screening any extract that shows inhibitory activity against the protein of interest is
further fractionated and those fractions are then rescreened and re-fractionated until a
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single compound with inhibitory properties is identified. This library was screened using
the radioactive HTS.

3.2.4.6- The Lankenau Chemical Genomics Center Library
The Lankenau Chemical Genomics Center (LCGC) Library consists of
approximately 120,000 drug-like compounds that follow the Lipinski rules. Any hits
obtained from this screen can be obtained in powder form from LCGC for further testing.
The entirety of the LCGC library was matrixed with 10 compounds per well, and each
compound in two wells, with the final concentration of each compound at 25 µM and was
screened with the radioactive HTS.

3.2.5 hMOF Crystallization with Merbromin
hMOF crystals were obtained using the hanging drop method at protein
concentrations between 6 and 8 mg/mL, mixed 1:1 with a reservoir buffer composed of
0.2 M ammonium acetate, 28% PEG 3350, and 0.1 M BisTris pH 6.5 and incubated over
reservoir buffer. After crystals formed, they were soaked in their well solution plus 10
mM merbromin and incubated over reservoir buffer for 2 days.

The crystals were

cryoprotected by a short soak in well solution plus 17% ethylene glycol, followed by flash
freezing in liquid nitrogen. Data was collected at BNL beamline X-29A. Diffraction data
was processed using HKL2000 (Otwinowski and Minor 1997) and the structure was
determined using molecular replacement with Phaser (Mccoy, Grosse-Kunstleve et al.
2007). Manual model building was carried out using Coot (Emsley and Cowtan 2004)
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and refinement was performed using Phenix (Adams, Afonine et al. 2010). Figures were
made using PyMOL

(The PyMOL Molecular Graphics System, Version 1.2r3pre

Schrödinger, LLC.)

3.2.6 Mechanism of Action (MOA) Assay
Mechanism of action assays were performed using the low throughput
radioactivity assay described in section 3.2.3.1. MOA assays were carried out following
the same procedures as for Michaelis-Menten curves for determining the Km and kcat of
an enzyme (described in section 2.3.4), the only difference is that they were performed
multiple times in the presence of a varying concentrations of compound. Briefly the
specific parameters for the data presented in this chapter are given here. We first mixed
hMOF at 50 nM with H4 peptide in a buffer containing 40 mM Tris (pH 8.0), 100 mM
NaCl, 800 µM Cys, and 7.5 µM BSA. Depending on which substrate was being tested,
H4 was either varied from 50 µM – 4 mM or saturating (4 mM). We began the assay by
adding
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C-acetyl CoA which was varied from 15 µM - 500 µM or saturating (500 µM) in

a final volume of 50 µL. The reaction proceeded for eight minutes to maintain steady
state conditions, and was repeated with 10 different concentrations of compound 115772
ranging from 0 µM to 200 µM for each different substrate concentration.
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3.3 Results and Discussion
3.3.1 Initial Validation of Primary Screening Hits
Our initial small molecule screening campaign identified 281 active compounds
that appeared to inhibit hMOF. These included 40 hits from the Spectrum/ NCC Library,
17 hits from the ChemDiv Library, and 224 hits from the LCGC library for an overall hit
rate of 0.17%. We first retested the hits using the primary screening assay from which
they were identified. Approximately 75% of the initial hit compounds showed no
inhibitory activity against hMOF upon retest and were eliminated from our pool of
potential lead compounds. The eliminated compounds included 24 hits from the
Spectrum/ NCC library, all of the compounds from the ChemDiv Library and 172
compounds from the LCGC library. Because the LCGC library was the last library we
screened, as well as the largest library, the initial validation steps were more intense
than other screens and are described in detail in section 3.3.5.
The NPDI Library screening failed to identify any lead compounds for further
testing. After several rounds of screening and fractionation, the only active compounds
identified were tannins. Tannins are reviewed in (Khanbabaee and van Ree 2001), and
the limited utility of tannins to be developed as inhibitors is discussed in (Beutler 2009).
Briefly, tannins are polyphenols found in high concentrations throughout all parts of a
plant. The poor prospects for development of tannins is rooted in their mechanism of
action, which is to non-covalently bind various proteins (Beutler 2009). Because of this,
there is little hope for tannins to be developed to specifically inhibit a protein of interest,
leading us to conclude our natural product screening with no pursuable results.
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3.3.4 Cysteine Reactive Compounds
Of the compounds that were confirmed from the second round of testing, 16 were
from the Spectrum Collection. These 16 compounds were next tested in a concentration
series using a secondary low throughput radioactivity assay resulting in only two
compounds being confirmed to inhibit hMOF: cystamine dichloride and merbromin
(Figure 11). Looking at the structures of these compounds, some chemical details were
immediately concerning regarding the specificity of these compounds as inhibitors. As
discussed throughout this thesis, hMOF relies on an active site cysteine for activity, and
both compounds identified contained moieties that could interfere in some way with that
cysteine. In the case of cystamine dichloride, the disulfide bond was particularly
disconcerting. Presumably the disulfide bond could cleave and form covalent adducts
with the active site cysteine of hMOF to inhibit the enzyme with very few functional
groups on the compound that would allow for the interactions with the active site to be
specific. With merbromin, the concern was that the mercury atom itself could react with
the hMOF active site cysteine. However, because the mercury atom was just a small
part of this compound, we continued our study of merbromin, hoping that the overall
structure of the compound, and not just the mercury itself, would contribute to specific
hMOF inhibition.
To further investigate the mechanism of inhibition of merbromin with hMOF, we
grew hMOF crystals and soaked the crystals with merbromin. We were able to collect a
data set on an hMOF crystal soaked with 10 mM of merbromin for two days (Figure 12).
What we immediately noticed from the Fo−Fc electron density maps from these crystals
was large bulbous density around cysteines even at high σ values implying that a heavy
metal was present at these locations. What was more important was that at lower σ
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Figure 11. Chemical structures of the two cysteine-reactive hits, cystamine dichloride
and merbromin, obtained from the high throughput screen of the Spectrum Collection.
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Figure 12. Fo-Fc density for hMOF soaked with merbromin. Fo−Fc density
(green) contoured at 5σ (inset 2.5σ) for hMOF (magenta) soaked with 10 mM of
merbromin for 2 days. The active site cysteine (C316) is colored cyan and shown
as sticks. Other cysteines with visible Fo−Fc density at 5σ are shown as magenta
sticks. Note in the inset that even at 2.5σ only density for a single metal on the
cysteine is visible with no apparent density for the merbromin compound as a
whole.
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values no further density was revealed in the Fo−Fc maps surrounding the metal,
implying that the whole compound was not present, only mercury. We concluded from
this data that there were likely mercury contaminants present in our compound sample
that could disable the protein with no contribution from the overall structure of the
merbromin compound, thus making the merbromin compound unsuitable for further
development as an hMOF inhibitor.
This data led us to include 800 µM free cysteine in future assay buffers in an
attempt to outcompete hMOF for cysteine reactive compounds, as discussed in the
previous chapter section 2.5.4. Furthermore, this data also warned us to be particularly
wary of compounds that would react with cysteine, which we would come across
repeatedly throughout the screening process, even in the presence of free cysteine in
the reaction buffer.

3.3.5 Confirmation of LCGC Active Compounds
3.3.5.1 Details on Initial Validation of Primary Screening Hits from LCGC
Similar to all other libraries, to validate the hits from the LCGC library we retested
the compounds in the format of the radioactive high throughput screen which eliminated
172 of the initial hits. Based on our screening compound concentration (25 µM) we
suspected that some compounds might inhibit via a mechanism of colloidal aggregation
(discussed in section 2.5.6). To eliminate these compounds we rescreened all 224 initial
hits from the LCGC screen in the presence and absence of 0.05% tween 20 (Figure 13).
A majority of the hits that maintained activity in the presence of a small amount of non-

66

Figure 13. Data comparing LCGC hits with and without 0.05% tween 20 Data shows
the 224 initial hits from the LCGC library as well as positive controls (Columns 2 and 24),
negative controls (Columns 1 and 23), and acetonyl CoA dose response control (blue
box) in the presence (right) and absence (left) of 0.05% tween 20. The nine compounds
selected for further characterization are indicated in red circles. Note that many hits lose
activity in the presence of 0.05% tween 20. Compounds that do not lose greater than
10% of their activity and are not selected for further testing are copper salts.
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ionic detergent were copper salts, and were eliminated from the list of potential inhibitors
due to their ability to disable the protein by binding the active site cysteine. We opted to
continue the testing with nine compounds that did not contain copper and varied in their
inhibitory activity by less than 10% in the presence or absence of tween 20.
We then further validated that these compounds were not acting through colloidal
aggregation by obtaining their powders from LCGC and performing IC50 studies using the
low throughput radioactivity assay in the presence and absence of tween 20 to confirm a
consistent IC50 and a Hill slope of ~1. As described in section 2.5.6, one way to ensure
that a given compound is not acting through colloidal inhibition is to ensure that addition
of a small amount of non-ionic detergent, which would disrupt colloidal aggregates, does
not disrupt the inhibitory properties of a compound. Another method which goes hand-inhand with the IC50 test is Hill slope analysis, where a Hill slope of ~1 implies noncooperative binding of inhibitor to protein. Of the nine compounds that were tested, four
compounds failed to show inhibitory activity, and were eliminated. We continued moving
forward with the remaining five compounds following this round of testing which showed
reproducible IC50 values and low Hill slopes (Figure 14, Table 2). It is worth noting that
at this point we noticed that most of our Hill slope values were greater than 1, which
considering that they were unaffected by tween 20, could be a sign that they were
irreversible inhibitors. The reversibility of the top compounds will be addressed in section
3.3.5.3.

68

Figure 14. Structures and IC50 values for five hits from the LCGC library in
the presence and absence of non-ionic detergent. Column 1: Chemical
structures of the five hits from the LCGC library. Column 2: IC50 curves for these
compounds in the absence of 0.05% tween 20. Column 3: IC50 curves for these
compounds in the presence of 0.05% tween 20. Table 2 gives IC50 calculated
values and Hill slopes from these graphs
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Table 2: IC50 values and Hill slopes calculated from the data presented in Figure 14
compared to values calculated for acetonyl CoA (data not shown). Error
represents the standard deviation calculated from duplicate trials.

14855

IC50 (µM)
no tween 20
14.7 ± 0.9

IC50 (µM)
0.05% tween 20
13.4 ± 0.9

Hill Slope
no tween 20
3.0 ± 0.5

Hill Slope
0.05% tween 20
2.9 ± 0.5

115772
128041
24727
15908
Acetonyl CoA

20 ± 2
11.6 ± 0.8
100 ± 30
12.1 ± 0.8
20 ± 2

16 ± 1
11 ± 3
70 ± 10
16 ± 4
19 ± 2

1.9 ± 0.4
3.0 ± 0.5
1.7 ± 0.4
3.4 ± 0.7
1.1 ± 0.2

2.8 ± 0.5
1.3 ± 0.4
1.9 ± 0.4
2±1
1.2 ± 0.1
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3.3.5.2 Thermofluor Assay Eliminated Two More LCGC Hits.
Initially, we had tested all nine of the top LCGC compounds at 100 µM in the
thermofluor assay and observed that none of the compounds significantly increased or
decreased the thermal stability of hMOF. Now that we confirmed five compounds that
had reproducible IC50 values, we proceeded to retest the effects that these compounds
had on the thermal stability of hMOF at higher concentrations using the thermofluor
assay. Each compound was tested at 200 µM and 400 µM. Compound 24727
destabilized hMOF by 6°C at 200 µM and compound 15908 had no effect on hMOF at
200 µM and destabilized hMOF by 0.75°C at 400 µM leading to the elimination of these
compounds. Compounds 14855, 128041, and 115772 displayed stabilizing effects on
hMOF (Figure 15). Compound 14855 had the least effect on hMOF, increasing the
apparent melting temperature (Tm) by only 0.6 °C and 0.9 °C for the respective
concentrations. Compound 128041 saw the greatest shift at 200 µM increasing the Tm
by 7.7 °C. However, this result was then complicated by a loss of 1.6 °C in the presence
of 400 µM of compound 128041. We suspected that at higher concentrations this
compound may start to exhibit poor behavior such as aggregation or poor solubility and
did not eliminate it from the study. The best overall behaving compound in the
thermofluor assay was 115772 which showed a consistent concentration correlated
increase of Tm with a 1.6 °C increase at 200 µM and a 3.5 °C increase at 400 µM.
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Figure 15. The top three LCGC hits stabilize hMOF in a thermofluor assay.
Normalized thermal denaturation curves for hMOF presence of 200 µM and 400 µM
compound or CoA are shown. SYPRO Orange fluorescence is reported, and the
inflection point for each curve is the melting temperature for the protein in the given
conditions.
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3.3.5.3 LCGC Hits are Irreversible Inhibitors
Because of the stabilization effects observed in our thermofluor data, we
proceeded to perform a kinetic mechanism of action (MOA) study starting with
compound 115772. However, in the MOA assay, no hMOF inhibition was observed at
any concentration of compound 115772 (Figure 16).
A major difference between the IC50 assays and the MOA assays are that the
MOA are performed under steady state conditions, while the IC50 assays are not.
Therefore, while the overall procedures are very similar, the reaction time for the IC50
assay is 1h (taking the reaction to ~40% completion so that suitable signal can be
observed at substrate Km), and the MOA reaction time is only 8 min (to assure that
reaction is linear and that less than 10% of substrates have been consumed). This data
led us to start thinking about on and off rates, and what might contribute to inhibition
which occurs in 1 hour but not in 8 minutes. This data also led us decide to test the
reversibility of these compounds, which the slightly elevated Hill slope values indicated
could be irreversible.
Along these lines, we performed the enzyme recovery assay, which is fully
described in section 2.5.5. Briefly, a 100 x enzyme solution is incubated with a
compound at 10 x IC50 concentration. Then, before performing the reaction, the
incubated solution is diluted 100x such that the enzyme is at 1 x and the inhibitor is 10 x
below the IC50. If inhibition is still observed, it indicates that the compound inhibits
irreversibly. For our purposes we wanted to further explore how our compound was
inhibiting hMOF on longer time scales, if it did not show inhibition in kinetic assays. This
experiment revealed that compounds 115772, 128041, and 14855 were all irreversible
inhibitors (Figure 17).
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Figure 16. Attempted Mechanism of Action (MOA) assays using
compound 115772. The legend indicates compound concentration. In this
assay we did not observe any inhibition.
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Figure 17. Data for enzyme recovery assays. Enzyme recovery assays with
hMOF and the top 3 LCGC compounds using merbromin as a control for
irreversible inhibition and acetonyl CoA as a control inhibitor for reversible
inhibition. Note that all three of the LCGC compounds display behaviors of
irreversible inhibitors.
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While irreversible inhibitors do not tend to be ideal, they are not necessarily
useless. Irreversible inhibitors can be useful if they can be made to be specific for a
given target, and specificity may arise from chemical interactions between the compound
and the target in areas surrounding the covalent interaction (Copeland 2005). Because
of this reason we decided to proceed with testing these compounds.

3.3.6 Resynthesis and Lack of Validation of LCGC Top Hits
Because we had a finite amount of our compound stocks from LCGC for testing,
we collaborated with Michelle Estrada in the laboratory of Jeff Winkler (Chemistry
Department, University of Pennsylvania) to synthesize our remaining compounds so that
we could study them further. Compound 115772 was synthesized first, however, the new
compound did not reproduce the results of the original. In a dose response trial this
newly synthesized compound did not show any inhibition against hMOF, and in a
thermofluor assay this compound was destabilizing at both 200 µM and 400 µM (Figure
18).
Similarly, the newly synthesized compound 128041 did not behave the same as
the initial compound. In fact, the newly synthesized 128041 could not be tested in any
meaningful way because it appeared to be totally insoluble in DMSO. These results led
to the obvious question of the integrity of the samples that we had previously been
working with, and as such, we sent the original compound samples of 115772, 128041,
and 14855 from LCGC for mass spectrometry analysis.
The LCMS chromatograms of compounds 115772, 128041, and 14855 can be
seen in Figure 19, Figure 20 and Figure 21, respectively, and reveal not only an overall
76

Figure 18: Resynthesis of compound 115772 failed to reproduce activity. Data
from the resynthesized compound 115772. Top. Compound 115772 failed to inhibit
hMOF in a concentration series. Bottom. Thermal denaturation of newly synthesized
compound 115772 reveals that it destabilizes hMOF. Addition of varying amounts of
CoA shown as a control.
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Figure 19: Mass spectrometry chromatogram for compound 115772. Compound
structure and molecular weight of compound 115772 is shown in the upper left.
Structure and molecular weights of hypothesized break down products shown in left
inset.
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Figure 20: Mass spectrometry chromatogram for compound 128041. Compound
structure and molecular weight of compound 128041 is shown in the upper left.
Structure and molecular weight of hypothesized break down product shown in left
inset.
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Figure 21: Mass spectrometry chromatogram for compound 14855. Compound
structure and molecular weight of compound 14855 is shown in the upper left.
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noisy mixture of compound masses in the sample but also a disappointing lack of a peak
for the alleged compounds that they each were supposed to contain. The mass
spectrometry chromatogram for compound 115772

(theoretical M.W. 335) was

especially noisy, with major peaks that were difficult to assign based on the structure
and molecular weight of the parent compound. We considered that the azo bond in
compound 115772 may cleave to give two compounds shown in (Figure 22, top) with
molecular weights of 166 and 173, however peaks representing these masses were not
observed in the chromatogram either. The chromatogram for compound 14855
(theoretical M.W 234) contained all major peaks with molecular weights higher than the
molecular weight of the compound itself and could not be assigned. The chromatogram
for compound 128041 (theoretical M.W 280,) however had a major peak at MW ~267
which our collaborators hypothesized could possibly be a breakdown product of the
parent compound, and also synthesized a related compound with similar functionality
(Figure 22, middle). Michelle Estrada synthesized these two compounds, however, they
also did not inhibit hMOF when tested in a concentration series using the radioactive low
throughput assay (Figure 22, bottom). At this point we were left with compounds of
unknown structure for which we did not have enough remaining sample for NMR
characterization. As a conclusion, we unfortunately had no choice but to drop the three
compounds as chemical structures could not be confirmed, or even identified, even
though they may have been potential true inhibitors.
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Figure 22: Resynthesis Details. Top: Proposed break down product of
compound 128041 (A) based on the mass spectrometry chromatogram and
related compound with similar functionality (B). Bottom: Neither compound A
nor B inhibited hMOF in a concentration series Bottom: Neither compound A
nor B inhibited hMOF in a concentration series

.
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3.4 Future Directions
Many of the lessons learned from this screening campaign are outlined, albeit
somewhat indirectly, in Chapter 2. Specifically, not confirming compound structures early
was one of the biggest flaws of this study. We confirmed that the compounds were not
merely misassigned by both confirming the accuracy of our library keys against those of
the scientists at LCGC, as well as mass confirmation of other compounds in the library
that were not hits in our screen (Figure 23). As a result of delaying the direct
identification of our hits, much time and effort was spent characterizing unknown
compounds that could potentially be either specific inhibitors or reactive breakdown
products.
Additionally, hMOF, or the MYST family in general, may just be difficult to target.
Similar to our own experience a paper reported in 2011 a high throughput screen against
the MYST protein, MOZ (Falk, Connor et al. 2011). In this study, ~243,000 lead-like
compounds were screened yielding ~1400 initial hits, and only a single scaffold met the
criteria of subsequent testing. A shortcoming of this study was that it never revealed the
chemical structure of the one successful scaffold, and no follow-up publications have
occurred to allow us to fully understand how successful this inhibitor actually was.
New approaches may be needed to successfully target hMOF or the MYST
family in general. In future screens in the laboratory, higher quality screening libraries
will be obtained, and lead compound structures will be confirmed before delving into
characterization. Also, fragment screening is an attractive option. We have already been
able to confirm that hMOF binds salicylic acid in the AcCoA binding pocket, through co-
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Figure 23: Mass spectrometry chromatogram for another compound from the
LCGC Library, showing that other wells contained the compounds that they were
assigned to contain with good purity, confirming the problem was not that
misassignment of compounds.
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crystallization experiments (Figure 24). If we could find other fragment compounds
which bind near the salicylate molecule we could design inhibitors based on the
combined structures of the fragments. Along these same lines we are currently
collaborating with Tyler Higgins of the Winkler Laboratory to design salicylic acid based
inhibitors based on the combined structural data of how salicylic acid binds hMOF, along
with the specific contacts in the region that are made by acetyl-CoA. Further future
directions will be discussed in Chapter 5.
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Figure 24: Salicylic acid (pink) bound to hMOF (cyan). hMOF is shown in cyan
with C316 and E350 shown in sticks. Salicylic acid binds hMOF in the AcCoA
binding pocket.
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CHAPTER 4
Structural and Functional Role of Acetyltransferase hMOF K274 Autoacetylation

This research was originally published in the Journal of Biological Chemistry, (McCullough,
Cheryl E.; Song, Shufei; Shin, Michael H.; Johnson, F. Brad; Marmorstein, Ronen. Structural and
functional role of acetyltransferase hMOF K274 acetylation. J Biol. Chem. 2016 Aug 26) © the
American Society for Biochemistry and Molecular Biology.
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4.1 Introduction
Because many histone acetyltransferases undergo autoacetylation to potentiate
cognate substrate lysine acetylation, and the mode and molecular role of such
autoacetylation is poorly understood, we sought to perform an in depth molecular
investigation of the mode of hMOF K274 acetylation. A mutational scan of hMOF K274
reveals that all amino acid substitutions of this residue are able to bind cofactor but are
significantly destabilized, both in vitro and in cells, and are catalytically inactive for
cognate histone H4 peptide lysine acetylation. The X-ray crystal structure of a hMOF
K274P mutant suggests that the reduced stability and catalytic activity stems from a
disordering of the residue 274-harboring α2-β7 loop. We also provide structural evidence
that a C316S/E350Q mutant, which is defective for cognate substrate lysine acetylation;
and biochemical evidence that a K268M mutant, that is defective for K274 chemical
acetylation in the context of a K274-peptide, can still undergo quantitative K274
autoacetylation. Together, these studies point to the critical and specific role of hMOF
K274 autoacetylation in hMOF stability and cognate substrate acetylation and argues
that binding of Ac-CoA to hMOF likely drives K274 autoacetylation for subsequent
cognate substrate acetylation.
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4.2 Experimental Procedures
4.2.1 Protein Expression and Purification
The recombinant hMOF HAT domain (residues 174-449) with an N-terminal
6xHis tag separated by a TEV protease recognition site was expressed and purified
essentially as previously described with some modifications (Yuan, Rossetto et al.
2012). Briefly, the plasmid was transformed into E. coli BL21(DE3) codon plus RIL
(Stratagene) cells and the protein was overexpressed in TB media, induced with 1mM
IPTG at OD 0.8-1.5, and grown at 15°C overnight. The cells were harvested and lysed
by sonication in lysis buffer (50 mM HEPES (pH 7.5), 0.5 M NaCl, 2 mM βmercaptoethanol,

5

mM

imidazole,

5%

glycerol,

0.1%

CHAPS

and

1

mM

phenylmethylsulfonyl fluoride) followed by centrifugation at 28,000g for 30 min at 4 °C.
The lysate supernatant was loaded onto Nickel charged NTA resin (Qiagen) equilibrated
with lysis buffer. The resin was washed with 10 column volumes of lysis buffer
containing 25 mM imidazole. The protein was eluted with lysis buffer containing 250 mM
imidazole buffer in 10 mL fractions. The eluent was concentrated and injected onto an
FPLC using a HiLoad Superdex 75 16/60 gel filtration column using sizing buffer (20 mM
HEPES (pH 7.5), 0.5 M NaCl). All hMOF mutants were created using the QuikChange
protocol from Stratagene. hMOF mutants were expressed and purified using the same
protocols as the wild type hMOF protein described above.
The recombinant MOZ HAT domain (residues 505-784) with an N-terminal 6xHis
tag separated by a TEV protease recognition site was expressed and purified as follows.
The plasmid was transformed into E. coli BL21(DE3) codon plus RIL (Stratagene) cells
and the protein was overexpressed in LB media, induced with 1mM IPTG at OD 0.6, and
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grown at 15°C overnight. The cells were harvested and lysed by sonication in lysis buffer
(50 mM Tris-HCl (pH 8.0), 0.5 M NaCl, 10mM β-mercaptoethanol, 5 mM imidazole, 5%
glycerol, 0.01% Triton-X and 1 mM phenylmethylsulfonyl fluoride) followed by
centrifugation at 28,000g for 30 min at 4 °C. The lysate supernatant was then loaded
onto Nickel charged NTA resin (Qiagen) equilibrated with lysis buffer and the resin was
washed with 10 column volumes of lysis buffer containing 25 mM imidazole. The protein
was then eluted with lysis buffer containing 250 mM imidazole buffer in 10 mL fractions.
The MOZ His tag was cleaved using a 6xHis-tagged TEV protease and the MOZ protein
was dialyzed overnight into low salt ion exchange buffer (40mM Tris-HCl, pH 7.0, 50 mM
NaCl, 1 mM DTT). The protein solution was then passed over another nickel column to
remove TEV protease and uncleaved MOZ. The resin was washed with approximately
three column volumes of low salt ion exchange buffer containing 20 mM imidazole. Flow
through and washes were pooled and loaded onto a 1 ml HiTrap SP cation exchange
column (GE Healthcare). The protein was eluted in ion exchange buffer with a salt
gradient (50–1000mM NaCl). Peak fractions were concentrated and run on a HiLoad
Superdex 75 16/60 gel filtration column (GE Healthcare) in sizing buffer (20 mM sodium
citrate, pH 5.5, 100 mM NaCl, 1 mM DTT). All MOZ mutants were created using the
QuikChange protocol from Stratagene. MOZ mutants were expressed and purified using
the same protocols as the wild type MOZ protein described above.

4.2.2 Enzyme Activity Assays
For comparing the activity of hMOF mutants (or MOZ mutants) to wild type, a
radioactive‐based enzymatic assay was employed as previously described (Yan, Harper
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et al. 2002). Briefly, 50 nM hMOF or 200 nM MOZ was incubated with 400 µM of
substrate peptide (H41-19 peptide for hMOF and H31-19 for MOZ) (GenScript) and 50 µM
14

C-acetyl CoA (50-60 mCi/ mmol Moravek) in reaction buffer (100 mM acetate, 50 mM

Bis Tris, 50 mM Tris at various pH values 100 mM NaCl, 800 µM cysteine and
0.25mg/mL BSA for hMOF and 40 mM Tris–HCl, pH 8.0, 100 mM NaCl, 1 mM DTT for
MOZ ) at a final volume of 50 µL and incubated at room temperature for 1 hour to allow
for 40-60% substrate conversion. To quench the reaction, 20 µL of the reaction mixture
was added to negatively charged P81 paper (Millipore). For kinetic studies of wild type
and K268M hMOF a saturating amount (500 µM) of radiolabeled

14

C-acetyl CoA and

varying concentrations of the substrate peptide (50–3000 µM) or a saturating amount of
substrate peptide (3000 µM) with varying concentrations of

14

C-acetyl CoA (15-500 µM)

were incubated with 50 nM hMOF (WT or K268M) in 50 µL of reaction volume for 8 min
at room temperature. Each reaction was performed in at least octuplicate. The counts
per minute (CPM) were converted to molar units using a standard curve of known

14

C-

acetyl CoA concentrations and values were calculated using GraphPad Prism version
5.0a, GraphPad Software, La Jolla California USA, www.graphpad.com. For both types
of radioactivity assays, filter papers were washed three times with 10 mM HEPES (pH
7.5) buffer, dried with acetone, and added to 4 mL of scintillation fluid. Signal was
measured with a Packard Tri-Carb 1500 liquid scintillation analyzer.

4.2.3 Thermal Denaturation Assay
Enzyme solutions at 1 µM in 40 mM Tris-HCl, pH 8.0 and 100 mM NaCl were
incubated in the presence or absence of 100 µM CoA for 30 minutes followed by
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addition of a 1:300 dilution of a 5000x concentrate of SYPRO® Orange (Molecular
Probes by Life Technologies) at a final volume of 20 µL in a MicroAmp Optical 384-well
reaction plate (Applied Biosystems) sealed with Optical Adhesive Covers (Applied
Biosystems). Samples were read using a 7900HT Real-Time PCR system (Applied
Biosystems) measuring from 20°C to 95°C using a 1% ramp rate. The dye was excited
at 490 nm and the emission light was recorded at 575 nm.

4.2.4 Crystal Structure Determination of MYST HAT Domains
All protein crystals were obtained using the hanging drop method at protein
concentrations between 6 and 8 mg/mL. Crystals of hMOF-K274P were obtained by first
concentrating the protein in the presence of 100 µM MG 149 (Selleck Chemicals), then
incubated with a 5 x molar excess of MG 149 before mixing 1:1 with a reservoir buffer
composed of 0.28 M Ammonium Chloride, 26%PEG 3350, and 0.1M BisTris pH 6.5 and
incubated over reservoir buffer. Crystals of hMOF-C316S/E350Q were obtained by
incubating protein with a 5 x molar excess of MG 149 before mixing 1:1 with a reservoir
buffer composed of 0.2 M Ammonium Chloride, 28%PEG 3350, and 0.1M BisTris pH
6.5. Despite the presence of MG 149 in the crystal preparatory conditions, no density for
this molecule was observed in the final electron density maps.
All native data sets were collected at APS 23 ID-B. Diffraction data were
processed using HKL2000 (Otwinowski and Minor 1997) for hMOF-K274P and XDS
(Kabsch 2010) for hMOF-C316S/E350Q and the structures were determined using
molecular replacement with Phaser (Mccoy, Grosse-Kunstleve et al. 2007). Iterative
cycles of manual model building were carried out using Coot (Emsley and Cowtan 2004)
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and refinement was performed using Phenix (Adams, Afonine et al. 2010). Figures were
made using PyMOL

(The PyMOL Molecular Graphics System, Version 1.2r3pre

Schrödinger, LLC.)

4.2.5 Cell Studies
DNA fragments containing V5/His-hMOF and V5/His-hMOF(K274R) were
obtained from pcDNA4-based plasmids (Yuan, Rossetto et al. 2012) and were cloned
into vector pLU-TREmin-MCS-pPURO using restriction sites SalI and AgeI. The rtTA3
gene was cloned into the SalI and BamHI sites of pLU-EF1-MCS-BLAST. Sequential
transfections of pLU-EF1-rtTA3-BlAST plasmids and V5/His‐hMOF plasmids into 293T
cells were performed using Lipofectamine 2000 (Invitrogen), according to the
manufacturer's guidelines. 10 µg/mL blasticidin and 1.5 µg/mL puromycin were used for
selection of successfully transfected 293T cells. 293T cells were maintained in DMEM
(with pyruvate, Mediatech) and 10% FBS at 37°C, under 6% CO2.
V5/His-hMOF and V5/His-hMOF (K274R) levels were assessed by western
blotting of lysates. Western detection of actin in a separate region of the same blot was
used as a loading control. The antibodies used were as follows: Anti-V5, P/N 46-0705,
Lot: 1707842 from Invitrogen, (1:2500), anti-actin (I-19), sc-1616, Lot: L1108, (1:2500),
and donkey anti-goat IgG HRP: sc-2020, Lot: G1615, (1:3000) from Santa Cruz Biotech,
and rabbit anti-mouse IgG HRP: ab97046, Lot: GR220045-5, (1:3000) from Abcam.
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4.2.6 Western Blots for Acetyl-Lysine
K274 acetylation levels of hMOF C316S/E350Q, hMOF K274A, hMOF WT and
hMOF K268M were assessed by western blotting of purified proteins. The antibodies
used were as follows: Acetylated-Lysine (Ac-K-103) Mouse mAb, 9681S, Lot: 11 from
Cell Signaling Technology, (1:1000), and Goat Anti-Mouse IgG (H+L)-HRP Conjugate:
L1721011, Lot 350000839, (1:4000) from Bio-Rad.
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4.3 Results
4.3.1 No other amino acid substitution at position 274 in hMOF can mimic the
potentiating role of K274 acetylation on hMOF thermal stability and cognate lysine
substrate acetylation
Because lysine 274 has been shown to have roles in both protein stability and
substrate binding and acetylation in vitro, we sought to determine if other amino acids
could mimic the effect of K274 autoacetylation. To do so, we prepared recombinant 6xHis-tagged wild-type and mutated hMOF HAT domains containing K274 mutated to
every other natural amino acid to assess protein thermostability and catalytic activity.
Following affinity purification using the 6x-His-tag, the wild-type and mutant proteins
eluted off of a size exclusion column at the same position, suggesting that the mutant
proteins were properly folded (Figure 25). Each mutant was tested for catalytic activity,
and to ensure that the K274 mutation was not merely affecting catalysis by changing the
pKa of the active site of the enzyme, activity was tested over a range of pH values
(Figure 26). Strikingly, these studies revealed that every K274 mutant protein was
significantly defective for cognate lysine acetylation, retaining less than 5% of wild-type
activity.
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Figure 25: Size-exclusion chromatograms of hMOF K274 mutants suggests
that they are properly folded. UV chromatograms of a representative subset of
hMOF K274 mutants applied to HiLoad Superdex 75 16/60 gel filtration column.
Each mutant displayed a similar profile and the major peak at approximately 75 mL
was collected.
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Figure 26: All hMOF K274 mutants are catalytically inactive. Relative
enzymatic activity of hMOF K274 mutants in comparison to the wild type hMOF
over a pH range from 5 to 9 measured as a function of H41-19 peptide acetylation is
shown in the chart. hMOF-WT activity at pH 8.0 is set to 1. All mutants retain less
than 5% of wild-type enzymatic activity. Error bars represent standard deviations
determined from quadruplicate measurements.
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To test the thermal stability of the K274 hMOF mutants, each one was tested in a
thermal denaturation assay. All mutants produced a melting curve revealing an average
loss of 9.3°C in thermal stability (with the exception of K274L, which did not produce a
curve from which an inflection point could be calculated) relative to wild-type hMOF
(Table 3 and Figure 27A). Interestingly, however, upon addition of 100 µM Co-enzyme
A (CoA) cofactor, the stability of the mutants increased an average of 7.9°C and wildtype hMOF stability increased by 6°C (Figure 27B and Table 3). These results
demonstrate that the hMOF K274 mutants have compromised thermal stability relative to
the wild-type protein but still retain the capacity for binding cofactor.
To assess whether the effect of the hMOF K274 mutations are general to other
MYST proteins, we prepared a subset of the hMOF mutants in the recombinant MYST
hMOZ HAT domain for enzymatic and thermal stability studies.

These studies

demonstrate that of the subset of corresponding K604 mutations (to A, R, M and Q)
tested, all of them had significantly compromised catalytic activity for cognate lysine
acetylation (Figure 28A) and thermal stability relative to wild-type hMOZ (Figure 28B
and Table 3). This result suggests that the importance of K274 acetylation on hMOF
activity and thermal stability is likely general to other MYST proteins. It should be noted
however, that the degree of protein stabilization mediated by autoacetylation at this
position may vary from protein to protein within the MYST family.
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Table 3: Average melting temperatures for hMOF K274 mutants and MOZ K604
mutants in the presence and absence of 100 µM CoA.
hMOF K274X

hMOF K274X+100µM

hMOZ K604X

hMOZ K604X +100µM

apo Tm (°C)

CoA Tm (°C)

apo Tm (°C)

CoA Tm (°C)

K (WT)

40.6 ± 0.4

46.9 ± 0.1

40.3 ± 0.5

45.2 ± 0.4

D

30.9 ± 0.6

42.8 ± 0.1

N.R.

N.R.

Q

30.9 ± 1.8

37.2 ± 0.2

36.0 ± 0.3

41.2 ± 0.1

T

29.6 ± 1.0

38.5 ± 0.0

N.R.

N.R.

G

31.7 ± 0.7

40.5 ± 0.4

N.R.

N.R.

M

30.5 ± 0.9

40.2 ± 0.4

34.5 ± 0.3

40.6 ± 0.2

H

32.3 ± 1.5

41.0 ± 0.4

N.R.

N.R.

E

29.3 ± 1.7

40.4 ± 0.5

N.R.

N.R.

R

31.8 ± 1.5

40.3 ± 0.2

37.6 ± 0.9

43.1 ± 0.2

F

30.1 ± 1.4

38.9 ± 0.2

N.R.

N.R.

S

31.5 ± 0.9

41.2 ± 0.7

N.R.

N.R.

C

30.0 ± 1.2

37.8 ± 0.5

N.R.

N.R.

P

32.7 ± 0.3

40.1 ± 0.4

N.R.

N.R.

Y

31.5 ± 2.0

38.8 ± 0.6

N.R.

N.R.

L

-

-

N.R.

N.R.

A

31.0 ± 0.5

40.1 ± 0.7

34.8 ± 0.6

39.9 ± 0.3

N

32.7 ± 0.3

40.0 ± 0.5

N.R.

N.R.

V

32.1 ± 1.0

38.5 ± 0.8

N.R.

N.R.

I

31.7 ± 0.6

38.3 ± 0.5

N.R.

N.R.

W

32.3 ± 0.4

34.1 ± 0.5

N.R.

N.R.

N.R.=Data not recorded. Note that data could not be fit for K274L. Error is determined from a
minimum of triplicate measurements.
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Figure 27: hMOF K274 mutants are thermally destabilized, but are still able to
bind cofactor. Normalized thermal denaturation curves for hMOF K274 mutants in
the absence (A) and presence (B) of 100 µM CoA are shown. SYPRO Orange
fluorescence is shown, and the inflection point for each curve is the melting
temperature for the protein.
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Figure 28: Subset of hMOZ K604 mutations reveals reduced catalytic activity
and thermal stability. (A) Enzymatic activity of MOZ K604 mutants as compared to
WT at pH 8.0. (B) Thermal denaturation experiment with MOZ-WT and K604
mutants in the presence or absence of 100 µM CoA.
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4.3.2 Crystal structure of hMOF K274P reveals loss of rigidity of the α2-β7 loop
In order to understand the molecular basis for the compromised catalytic activity
and thermal stability of the hMOF K274 mutants relative to the wild-type protein, we
attempted to obtain crystals of each of the hMOF K274 HAT domain mutants for X-ray
structure determination. We were only able to obtain crystals of the hMOF-K274P HAT
domain mutant, which formed in space group P212121 with one molecule in the
asymmetric unit and diffracted to 2.6 Å resolution. The structure was refined to an
Rwork/Rfree of 24.0/27.6% with good geometry (Table 4). The structure overlays very well
with the wild type hMOF HAT domain (PDB code 3QAH) with a RMSD of 0.85 Å2
(excluding the α2-β7 loop). Strikingly, in contrast to the wild-type hMOF structure
containing the acetylated K274, which shows ordered electron density corresponding to
the α2-β7 loop (Figure 29A), the hMOF-K274P mutant shows no clear density for the
α2-β7 loop (Figure 29B).

These studies suggest that hMOF K274 acetylation

contributes to the integrity of the α2-β7 loop of the activated protein. Notably, the active
site C316 and E350 residues of hMOF-K274P are in the same position as in the wild
type structure (Figure 29C), demonstrating that the α2-β7 loop and acetylated K274 do
not contribute to orienting the key catalytic active site residues. Although it is also
possible that the introduction of a proline residue, rather than loss of acetyllysine could
be responsible for the disorder of the α2-β7 loop, the observation that the hMOF K274P
has a similar thermal stability to all other hMOF K274 mutants, suggests that the
absence of acetyllysine at least contributes to the observed disorder of the α2-β7 loop.
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Table 4: Data statistics for crystal structures of hMOF-K274P and hMOF-C316S/
E350Q.
hMOF-K274P

hMOF-C316S/E350Q

Space group

P212121

P212121

Unit cell dimensions

a=46.094, b=55.846,
c=122.405

a=46.148, b=55.676,
c=122.311

Resolution range (Å)

36.82 - 2.598

27.84 - 2.166

Unique reflections

10235 (994)

17365 (1682)

Multiplicity

5.9 (5.9)

5.5 (5.5)

Completeness (%)

99.9 (99.8)

99.6 (99.6)

Rmerge (%)

11.2 (64.9)

5.9 (61.5)

I/σ

18.05 (2.5)

10.3 (1.2)

23.96/ 27.57

19.05/ 23.37

Bonds (Å)

0.006

0.008

Angles

0.91

0.90

Protein

41.16

44.17

Water

34.95

42.93

Ions

37.28

47.4

Favored

95

97

Allowed

5

3

Outliers

0

0

Crystal parameters

Data collection

Refinement statistics
Rwork/Rfree (%)
Root-mean-square deviation

Average B-factor (Å)

Ramachandran statistics (%)

Values in parenthesis are for the highest resolution shell.
103

Figure 29: The hMOF-K274P structure reveals a loss of rigidity in the α2-β7
loop. Omit Fo-Fc density (green) contoured at 3σ for the α2-β7 loop of hMOF WT
(PDB ID 3QAH)(A) and hMOF K274P (B). Note the significant lack of density for the
α2-β7 loop caused by introduction of the hMOF K274P mutation. (C) Comparison of
the wild-type and K274P hMOF active sites.
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4.3.3 Autoacetylation of K274 does not require active site catalytic residues C316 and
E350
To investigate the mode of K274 autoacetylation, we prepared a hMOF
C316S/E350Q HAT domain double mutant and asked whether this mutant is capable of
K274 autoacetylation. We first prepared hMOF C316S/E350Q in bacteria and confirmed
that this mutant had no detectable activity against a cognate substrate lysine in the form
of a 19-residue histone H4 N-terminal peptide, while the wild-type hMOF HAT domain
showed robust activity (Figure 30A). To determine the K274 autoacetylation state of
hMOF C316S/E350Q, we performed a western blot using a pan-acetyl lysine antibody,
which indicated that the hMOF C316S/E350Q mutant was acetylated (Figure 30B). We
also crystalized this mutant and determined its structure to 2.17 Å resolution. The
structure was refined to an Rwork/Rfree of 19.1/23.4% with good geometry (Table 4).
Strikingly, the refined structure revealed that K274 was acetylated with full occupancy
(Figure 30C). This observation demonstrates that K274 autoacetylation does not require
the active site catalytic residues C316 and E350.
We have previously demonstrated that an isolated peptide of the α2-β7 loop can
be chemically acetylated at residue K274 and that the basic nature of native residue
K268 or a mutant residue R268 supports K274 autoacetylation, and an uncharged
K268M mutant does not (Olia, Barker et al. 2015). To test the importance of K268 for
K274 autoacetylation and subsequent hMOF cognate lysine substrate acetylation in the
context of the folded hMOF HAT domain, we prepared the recombinant hMOF K268M
HAT domain mutant for enzymatic analysis against a histone H4 cognate lysine
substrate for comparison with the wild-type hMOF HAT domain. Surprisingly, the kinetic
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Figure 30: hMOF-C316S/E350Q is autoacetylated on K274. (A) Comparison of
histone H4 acetylation activity of hMOF WT and hMOF C316S/E350Q. (B) Western
blot using a pan-acetyl lysine antibody comparing the amount of protein present on
the membrane to the signal present on exposed film. (C) Structure of the hMOFC316S/E350Q mutant showing simulated annealing electron density at 1.5σ around
the acetylated K274. S303 is shown as a point of reference.
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Figure 31. hMOF WT and hMOF K268M share very similar kinetic profiles.
Michaelis-Menten curves are shown for hMOF-WT and hMOF-K268M against
acetyl CoA (A) and histone H4 peptide (B) Different kcat values were calculated for
data in each graph to demonstrate similarities in each individual case without bias
from averaging. To calculate kcat for this data, Vmax was divided by the total enzyme
concentration of 50nM. Error bars represent standard deviations determined from
a minimum of octuplicate measurements.
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parameters for the wild type and K268M mutant enzyme are remarkably similar (Figure
31). A western blot using a pan-acetyl lysine antibody confirmed that the hMOF K268M
mutant is autoacetylated at wild-type levels (Figure 30B). These results suggest that in
the context of the folded hMOF HAT domain, K268 does not contribute significantly to
K274 autoacetylation and that autoacetylation may be promoted by Ac-CoA binding and
positioning for effective K274 autoacetylation.

4.3.4 Autoacetylation of K274 increases hMOF half-life in cells
Our findings that K274 autoacetylation plays a specific and precise role in
thermal stability of the hMOF HAT domain in vitro, led us to ask whether K274
acetylation is required for hMOF protein stability in cells. To measure the stability of
hMOF and hMOF (K274R) within cells, we expressed V5-tagged versions of the proteins
under the control of a Tet-On promoter. Doxycycline was added to induce steady-state
levels of the proteins, and then the rate of protein decay was followed after removal of
doxycycline and the addition of cyclohexamide to block protein synthesis.
K274R decayed more rapidly than the wild type protein (Figure 32A).

hMOF-

The mutant

protein also decayed more rapidly than wild type when the experiment was performed
without cyclohexamide, thus ruling-out potential contributions from other effects of the
drug (e.g. inhibition of autophagy) (Figure 32B). These findings demonstrate that the
K274R mutation destabilizes hMOF in vivo, and indicate that hMOF K274
autoacetylation contributes to protein stability in cells.
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Figure 32: hMOF-WT shows a longer half-life than hMOF-K274R in cells. (A)
The levels of V5-tagged hMOF-WT and hMOF-K274R were followed by
immunoblotting at the indicated time points after doxycycline withdrawal and
treatment with cyclohexamide. (B) Same as (A), except without cyclohexamide.
Immunoblotting for actin on the same blot provides a loading control.
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4.4 Discussion
The results described here reveal that an autoacetylated lysine residue at
position 274 of hMOF contains the essential specific chemical properties to promote
hMOF stability and activity. Strikingly, we find that hMOF K274 autoacetylation cannot
be mimicked by other residues, arguing for the unique chemical properties of an
autoacetylated K274 residue in hMOF catalysis. While previous reports have proposed
that hMOF K274 autoacetylation may be required to ‘unlock’ the protein off state by
making the catalytic E350 available for the catalytic reaction and making the cognate
lysine substrate binding site more accessible (Sun, Guo et al. 2011, Yuan, Rossetto et
al. 2012), we have found that mutations of K274 to very small amino acids such as
glycine or alanine do not activate the protein. These data would suggest that hMOF
K274 autoacetylation also plays a more direct, positive role in the active state of the
enzyme, rather than merely counteracting reactivity in the off state. All but one of the
hMOF K274 mutants were demonstrated to bind CoA, and the K274P crystal structure
reveals that the key C316 and E350 catalytic residues are unperturbed. The α2-β7 loop,
however, was observed to be disordered in the hMOF-K274P structure, consistent with
the loss of thermal stability for the K274 mutants in vitro and the reduced half-life to
hMOF-K274R in cells. These observations demonstrate that in addition to facilitating
cognate lysine substrate binding (Yuan, Rossetto et al. 2012), hMOF K274
autoacetylation promotes protein stability to also indirectly contribute to cognate lysine
substrate catalysis. We previously reported on a structure of hMOF in which the α2-β7
loop could be modeled in two alternate conformations, one in which K274 was
acetylated and another where K274 was unacetylated (Yuan, Rossetto et al. 2012).
Interestingly, the α2-β7 loop could be traced in both cases, however K274 refined to a
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higher B-factor in the unacetylated relative to acetylated form, 36.6 Å2 vs. 30.9 Å2,
respectively, consistent with the greater rigidity of α2-β7 loop when K274 is acetylated.
While autoacetylation of hMOF K274 has been demonstrated to be required for
cognate histone substrate binding (Yuan, Rossetto et al. 2012), no MYST family proteins
have been crystallized with their cognate lysine peptide substrates. To gain insights into
how hMOF might recognize its cognate substrate and how the K274-containing α2-β7
loop might participate in this recognition, we aligned the structurally similar Hat1 HAT of
the Hat1/Hat2/H4 peptide crystal structure (PDB ID 4PSW) with hMOF (PDB ID 3QAH).
This superposition demonstrates that a Hat1 loop containing E162-D168 overlays well
with the α2-β7 loop of hMOF (Figure 33). In the Hat1 structure, four of six residues in
this region are reported to make interactions with the H4 peptide (E162, A163, N165,
and I167) (Li, Zhang et al. 2014). We hypothesize that the same trend may extrapolate
to the α2-β7 loop of hMOF such that the hMOF α2-β7 loop might be used for cognate
histone H4 peptide recognition in a similar way. Similar ideas have been proposed
comparing hMOF to Gcn5 bound to H3 substrate (Kadlec, Hallacli et al. 2011, Sun, Guo
et al. 2011).

Such a model would explain how disruption of the α2-β7 loop may

compromise histone H4 binding for cognate lysine acetylation.
We provide crystallographic evidence that hMOF K274 becomes acetylated in
the absence of both known catalytic residues, C316 and E350, which makes a strong
argument for the autoacetylation at this position to not be mediated by acid/base
catalysis as proposed for cognate lysine substrate acetylation. We have also found that
in contrast to the trends seen in hMOF peptides (Olia, Barker et al. 2015), mutation of
the preceding basic residue, K268 in context of the HAT domain does not appear to
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Figure 33: Overlay of Hat1 bound to H4 peptide structure with hMOF
structure reveals that hMOF α2-β7 loop likely makes contacts with H4. hMOF
is shown in cyan with the α2-β7 loop in navy, Hat1 is shown in light pink with the
E162-D168 region (corresponding to the α2-β7 loop in hMOF) shown in red. A
region of the H4 peptide from the Hat1 structure is shown in magenta.
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affect enzyme activity. Thus, the mechanism for the regulation of hMOF K274 appears
likely to be driven more by Ac-CoA binding and positioning, potentially to prime hMOF
for cognate lysine acetylation.
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CHAPTER 5
Conclusions and Future Directions
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5.1 Identification of hMOF Inhibitors
5.1.1 Conclusions
We were unable to identify any inhibitors from our high throughput screening
campaign of hMOF. While we did identify three compounds that irreversibly inhibited
hMOF with stabilizing effects, our inability to confirm the identity of these compounds
made it impossible for us to characterize them further. We also encountered numerous
false hits throughout our screening campaign, with one major culprit being colloidal
aggregates. One study has reported that in a screening campaign testing compounds in
a concentration series from 3 nM to 30 µM, 95% of hits were shown to act through
aggregate-based inhibition. Furthermore, 60% of the compounds that formed colloidal
aggregates at 5 µM did not form aggregates at 1 µM and aggregate formation increased
with increasing compound concentration (Feng, Simeonov et al. 2007). Therefore, it is
not quite so surprising that many of our hits were colloidal aggregates at 20-25 µM. It is
also important to remember that even with these high screening concentrations, our
overall hit rate was fairly low at 0.17%. We had initially tried screening some libraries at
much lower compound concentrations (5 µM) which yielded no hits at all. Additionally,
even the best known MYST acetyltransferase inhibitors have IC50 values greater than 5
µM (discussed in section 1.6). Taken together, these data suggest that it may be very
hard to target the available chemical space using small molecules in the MYST enzymes
and that perhaps small molecule HTS may not be the best approach for finding hMOF
inhibitors. For this reason and others, I propose that crystallographic fragment screening
would be a reasonable route to finding hMOF inhibitors.
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5.1.2 Future Directions: Crystallographic Fragment Screening with hMOF
Fragments differ from small molecule drug-like compounds in a variety of ways.
Fragments have lower molecular weight, increased polarity and solubility, and less
chemical complexity. The goal of fragment screening is to either find multiple fragments
which bind in adjacent regions of a target protein and then design an inhibitor by linking
those fragments or to find a single fragment and expand it based on known structural
information (Joseph-McCarthy, Campbell et al. 2014). Because of the limited number of
contacts made by a fragment, enzymatic activity readouts are generally insufficient for
identifying fragment binders. Rather, assays that detect binding, such as SPR, NMR,
ITC, and crystallography as well as some other are employed (Joseph-McCarthy,
Campbell et al. 2014).
There are three major criteria that should be met to successfully perform
crystallographic fragment screening. Firstly, X-ray diffraction resolution will generally
need to be better than 2.8 Å to identify the bound fragment. Secondly, crystals must be
resilient to soaking conditions, and thirdly the crystal conditions/ crystal packing must
allow for fragment binding (Patel, Bauman et al. 2014). hMOF has already been proven
to meet all of these criteria. hMOF crystals, in my hands, frequently diffract to better than
2.8 Å at synchrotron beam sources. I have also subjected multiple hMOF crystals to
multiple-day long soaks with various compounds without fracturing crystals or losing
diffraction. Additionally, not only can CoA be easily soaked into pre-formed crystals,
demonstrating the availability of the binding pocket in the crystallographic form, but I
have also observed the fragment-sized compound salicylic acid bound to hMOF. A
hurdle that is often reported in crystallographic fragment screening is when crystal
conditions bind the crystal, causing fragments to need to compete with crystallization
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conditions (Patel, Bauman et al. 2014). hMOF crystals in my hands, however, have been
void of visible crystal condition molecules in the structure, with mostly just water and ions
occupying the protein pockets. For these reasons, I think hMOF would be an ideal
candidate for crystallographic fragment screening.
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5.2 Autoacetylation of K274
5.2.1 Conclusions
A mutational scan of hMOF K274 revealed that all amino acid substitutions of this
residue were able to bind cofactor but were significantly destabilized, both in vitro and in
cells, and are catalytically inactive for cognate histone H4 peptide lysine acetylation. The
X-ray crystal structure of a hMOF K274P mutant suggested that the reduced stability
and catalytic activity stemmed from a disordering of the residue 274-harboring α2-β7
loop. While we hypothesized that the disordering of this loop results in a loss of binding
to the H4 peptide, we were unable to confirm this hypothesis using a variety of
biochemical techniques due to the relatively weak affinity of hMOF for the substrate
histone tail. Furthermore, there are no crystal structures of any of the MYST family
proteins bound to the histone tail. As future directions for this project, I would like to
explore ways to improve H4 tail binding/ affinity to hMOF so that it can be crystallized
and further studied. Additionally, the loss of catalytic activity for cognate substrate
correlated with the mutation of K274 raises the question of whether this residue is
involved in the catalysis for the MYST family. In this respect I also propose a future
direction of tracking the K274 acetyl group to see if it is transferred from the enzyme to
the substrate. Lastly, throughout the course of this project I have attempted a number of
other experiments to learn more about the role of K274 acetylation that were overall,
unsuccessful. Specifically, I attempted to make a series of hMOF double mutants that
would recapture the stability of the stability of the α2-β7 loop. For the sake of record and
for a fuller understanding of the direction of my future studies, I will detail these
attempted experiments at the conclusion of this section.
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5.2.2 Future Directions: Improving hMOF Affinity for H4 Tail
One hypothesis as to why none of the MYST family acetyltransferases have
been crystallized with their cognate substrate peptides is because of the sequential
nature of their ping-pong catalytic mechanism. Before the H4 peptide binds, AcCoA must
first bind the active site, transfer an acetyl group to the active site cysteine, and then exit
the active site. It is reasonable to speculate that the hMOF crystals have never revealed
H4 binding is because the active site is not primed to bind H4. As such I would like to
design an hMOF mutant where the active site mimics the active site following acetyl
transfer from AcCoA to the active site cysteine, perhaps by mutating the cysteine to a
glutamine in an attempt to mimic acetyl-cysteine, and then use this mutant to attempt cocrystallization with the H4 peptide.
Another problem that could be causing the difficulty in co-crystallizing the H4
peptide with hMOF is the low affinity of the protein towards the peptide. Perhaps to
overcome this I could create an hMOF construct that has a section of the H4 tail cloned
into the N or C terminal of the protein with a linker. This would allow for a higher local
concentration of H4 tail in constant proximity with its binding site. Current crystallization
protocols for hMOF leave the 6xHis tag and TEV cleavage site intact; implying that
excess peptide on the N-terminus of the protein will not abrogate crystallization. If this
region were replaced with the relevant sequence of the H4 peptide it could ensure a 1:1
mixture of hMOF:H4 peptide in our crystals which may induce the H4 binding due to the
increased local concentration.
Crystallographic information on how hMOF binds the substrate peptide would not
only allow us to confirm our hypothesis on the role of the autoacetylation of hMOF in
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catalysis, but would also provide a key piece of information on the MYST family that has
been thus far missing.

5.2.3 Future Directions: Tracking the K274 Acetyl Group
Every K274 mutant enzyme was significantly defective for cognate lysine
acetylation, despite being properly folded, which raises the question of whether this
amino acid is a catalytic residue for the MYST family. To investigate this issue, I propose
an experiment to track the acetyl group on K274 to determine if it can be transferred to a
cognate substrate.
To perform this experiment, I would use a 6xHis tagged WT hMOF as well as a
6xHis tagged hMOF C316S mutant to control for acetyl transfer occurring through the
active site cysteine. Each enzyme would first be incubated with the promiscuous yeast
deacetylase

HST2

and

NAD+ to

remove

any

existing

acetylation. Following

deacetylation, each hMOF enzyme would be isolated by binding to nickel resin in a
column and washing away HST2. Next the hMOF would be incubated with
to allow transfer of

14

C-AcCoA

C acetyl to K274. Following the incubation, the enzymes would be

washed to remove free
CoA to displace any

14

14

14

C-AcCoA, followed by a wash with a saturating amount of cold

C-AcCoA that may remain bound to the AcCoA binding pocket of

the enzymes. A sample of both WT hMOF and hMOF C316S would be collected at this
point to measure the degree of acetylation of the samples. Next, to measure acetyl
transfer, both the WT and mutant hMOF would be incubated with H4 peptide. Following
incubation with the H4 peptide, the H4 peptide would be eluted off the columns and
collected. The nickel-bound hMOF would be washed again to remove any remaining H4
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peptide, and another sample would be collected to measure the degree of acetylation of
the hMOF enzymes following acetyl transfer. The amount of acetylation on the collected
H4 peptide or the difference in acetylation between pre- and post- H4 incubated enzyme
would indicate the amount of acetyl transfer that occurred for either of the two enzymes.
Then comparing the difference between the amount of acetyl transferred for the WT
hMOF and the hMOF C316S mutant to decipher to what extent, if any, the acetyl
transfer is occurring through K274.
One caveat of this proposed experiment is that trying to isolate the possible
catalytic contribution of K274 from the active site cysteine could be very difficult to
achieve. A previous study has demonstrated that when incubated with AcCoA, the
MYST active site cysteine will become acetylated (Yan, Harper et al. 2002) While I
propose using a hMOF C316S mutant as a control, this mutant has been shown to be
catalytically inactive against cognate substrate and likely would not transfer acetyl group
to the H4 peptide. Similarly, I could include a control of a hMOF K274Q in an attempt to
isolate the catalytic contribution of the active site cysteine, but again, hMOF K274
mutants have been demonstrated to be catalytically inactive. Thus, the major difficulty in
assessing the catalytic potential of lysine 274 will be isolating the catalytic contribution of
the active site cysteine.
Alternatively, another method we could use to help differentiate between
acetylation originating from the cysteine versus the lysine would be mass spectrometry.
For this two-part experiment I would first want to determine if the acetyl group on the
active site lysine 274 were sufficiently labile to be transferred in the absence of a
deacetylase, for instance. To test this I would once again deacetylate the hMOF with
HST2 to remove any preexisting acetylation. Then I would incubate the enzyme with 13C121

AcCoA, and take a sample for mass spectrometry to ensure that the K274 is acetylated
with

13

C-acetyl. Next I would wash away the

13

C-AcCoA, and add an excess of

12

C-

AcCoA (cold) and H4 to allow the enzyme to go through several acetylation cycles, then
wash the hMOF again and take another sample for mass spectrometry. To avoid
different peptide lengths in the mass spectrometry data for acetylated versus
deacetylated lysines, the hMOF would be denatured and treated with

12

C-acetic

anhydride prior to trypsinization such that cut sites are uniform and only occur at
arginines. If the lysine 274 remains acetylated with

13

C-acetyl, this would indicate that

this residue is not participating in catalysis and the experiment is concluded. If the lysine
is not acetylated with

13

C-acetyl, but rather

12

C-acetyl, then I move on to the second

experiment to confirm that the acetyl group from lysine 274 is transferred to the
substrate. For this experiment I would incubate a large amount (low micromolar) of
hMOF with

13

C-AcCoA once again, and wash. Then I would add an equimolar amount of

H4 as well as an excess of cold 12C-AcCoA. I would then isolate the H4 peptide following
the reaction and use mass spectrometry to determine if

13

C-acetyl is transferred to the

H4 peptide. This experiment would still have the caveat that I could not ensure that the
13

C-acetyl was not traveling through the active site cysteine, especially as an acetyl

cysteine is generally not stable enough to be detected in mass spectrometry
experiments. However, if I were able to show that the acetyl-lysine were labile enough to
transfer the acetyl group from the first experiment, then perhaps I could, in this case, use
a hMOF C316S mutant to show some percentage of acetyl transfer through K274. Of
course the caveat here becomes that if the catalytic mechanism requires both the
cysteine and the lysine, then once again teasing out the individual contributions of either
amino acid becomes complicated.
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5.2.4 Attempted Future Directions: Stabilizing the α2-β7 Loop
Because our crystallographic data from the K274P structure revealed a loss of
rigidity in the α2-β7 loop of hMOF, and because we hypothesized that the positioning of
this loop was likely important for cognate substrate binding, we sought to make
additional mutations in hMOF that would stabilize this loop in the presence of a K274
mutation. Specifically, because acetylated K274 hydrogen bonds to S303, I sought to
make mutations at position 303 that could potentially make hydrogen bonds to various
K274 mutants. First I tried to mimic the acK274/S303 interaction by making a hMOF
K274S/S303Q mutant that would, in essence, swap the two residues, using the
glutamine as an acetylated lysine mimic. This mutant however was insoluble, and I
hypothesized that perhaps the glutamine, being shorter in length than an acetylated
lysine, was not long enough to be in close enough proximity to S274 for hydrogen
bonding. Following this logic, I made two more mutants, which I hypothesized would
have the length required for hydrogen bonding: hMOF K274N/S303Q and hMOF
K274Q/S303Q. Despite the fact that both of these double mutants were soluble, which
was an improvement on the prior hMOF K274S/S303Q mutant, they both thermally
destabilized the hMOF enzyme by an even greater degree than their K274 single mutant
counterparts. Ultimately, I was unable to reestablish the stability of the α2-β7 loop.
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Table 5: Frequently used abbreviations
Abbreviation
AcCoA

Full Name
Acetyl Coenzyme A

acK

acetyl lysine

CBP

CREB-binding protein

CoA

Coenzyme A

CPM

counts per minute

GNAT

GCN5-related N-acetyltransferase

GST
H4
H4K16

Glutathione S-transferase
Histone H4
Histone H4 lysine 16

HAT

histone acetyltransferase

HAT1

Histone acetyltransferase 1

hMOF

human males absent on the first

HTS

High Throughput Screen

LCGC

Lankenau Center for Chemical Genomics

MOF

males absent on the first

MOZ

monocytic leukemia zinc-finger protein

MYST

(named for founding members) MOZ, YBF2/SAS3, SAS2, and Tip60

NPDI

Natural Product Discovery Institute

PAINS

Pan-assay interference compounds

PCAF

P300/CBP-associated factor

PTM

Post translational modification

TEV

Tobacco etch virus

Tip60

60 kDa Tat-interactive protein
124

REFERENCES

"Genscript TFA Removal Service http://www.genscript.com/tfa_removal_service.html."
Retrieved
December
16,
2015,
2015,
from
http://www.genscript.com/tfa_removal_service.html.
Adams, P. D., P. V. Afonine, G. Bunkoczi, V. B. Chen, I. W. Davis, N. Echols, J. J.
Headd, L. W. Hung, G. J. Kapral, R. W. Grosse-Kunstleve, A. J. McCoy, N. W. Moriarty,
R. Oeffner, R. J. Read, D. C. Richardson, J. S. Richardson, T. C. Terwilliger and P. H.
Zwart (2010). "PHENIX: a comprehensive Python-based system for macromolecular
structure solution." Acta Crystallographica Section D-Biological Crystallography 66: 213221.
Akella, J. S., D. Wloga, J. Kim, N. G. Starostina, S. Lyons-Abbott, N. S. Morrissette, S.
T. Dougan, E. T. Kipreos and J. Gaertig (2010). "MEC-17 is an alpha-tubulin
acetyltransferase." Nature 467(7312): 218-222.
Albaugh, B. N., K. M. Arnold, S. Lee and J. M. Denu (2011). "Autoacetylation of the
histone acetyltransferase Rtt109." J Biol Chem 286(28): 24694-24701.
Allfrey, V. G., R. Faulkner and A. E. Mirsky (1964). "Acetylation and Methylation of
Histones and Their Possible Role in the Regulation of Rna Synthesis." Proc Natl Acad
Sci U S A 51: 786-794.
Baek, S. H., K. A. Ohgi, D. W. Rose, E. H. Koo, C. K. Glass and M. G. Rosenfeld (2002).
"Exchange of N-CoR corepressor and Tip60 coactivator complexes links gene
expression by NF-kappaB and beta-amyloid precursor protein." Cell 110(1): 55-67.
Baell, J. and M. A. Walters (2014). "Chemistry: Chemical con artists foil drug discovery."
Nature 513(7519): 481-483.
Baeza, J., M. J. Smallegan and J. M. Denu (2015). "Site-specific reactivity of
nonenzymatic lysine acetylation." ACS Chem Biol 10(1): 122-128.
Balasubramanyam, K., M. Altaf, R. A. Varier, V. Swaminathan, A. Ravindran, P. P.
Sadhale and T. K. Kundu (2004). "Polyisoprenylated benzophenone, garcinol, a natural
histone acetyltransferase inhibitor, represses chromatin transcription and alters global
gene expression." J Biol Chem 279(32): 33716-33726.
Balasubramanyam, K., V. Swaminathan, A. Ranganathan and T. K. Kundu (2003).
"Small molecule modulators of histone acetyltransferase p300." J Biol Chem 278(21):
19134-19140.
Balasubramanyam, K., R. A. Varier, M. Altaf, V. Swaminathan, N. B. Siddappa, U.
Ranga and T. K. Kundu (2004). "Curcumin, a novel p300/CREB-binding protein-specific
inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins
125

and histone acetyltransferase-dependent chromatin transcription." J Biol Chem 279(49):
51163-51171.
Berndsen, C. E., B. N. Albaugh, S. Tan and J. M. Denu (2007). "Catalytic mechanism of
a MYST family histone acetyltransferase." Biochemistry 46(3): 623-629.
Berns, K., E. M. Hijmans, J. Mullenders, T. R. Brummelkamp, A. Velds, M. Heimerikx, R.
M. Kerkhoven, M. Madiredjo, W. Nijkamp, B. Weigelt, R. Agami, W. Ge, G. Cavet, P. S.
Linsley, R. L. Beijersbergen and R. Bernards (2004). "A large-scale RNAi screen in
human cells identifies new components of the p53 pathway." Nature 428(6981): 431437.
Beutler, J. A. (2009). "Natural Products as a Foundation for Drug Discovery." Curr
Protoc Pharmacol 46: 9 11 11-19 11 21.
Blanco-Garcia, N., E. Asensio-Juan, X. de la Cruz and M. A. Martinez-Balbas (2009).
"Autoacetylation regulates P/CAF nuclear localization." J Biol Chem 284(3): 1343-1352.
Borrow, J., V. P. Stanton, Jr., J. M. Andresen, R. Becher, F. G. Behm, R. S. Chaganti, C.
I. Civin, C. Disteche, I. Dube, A. M. Frischauf, D. Horsman, F. Mitelman, S. Volinia, A. E.
Watmore and D. E. Housman (1996). "The translocation t(8;16)(p11;p13) of acute
myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein." Nat
Genet 14(1): 33-41.
Bowers, E. M., G. Yan, C. Mukherjee, A. Orry, L. Wang, M. A. Holbert, N. T. Crump, C.
A. Hazzalin, G. Liszczak, H. Yuan, C. Larocca, S. A. Saldanha, R. Abagyan, Y. Sun, D.
J. Meyers, R. Marmorstein, L. C. Mahadevan, R. M. Alani and P. A. Cole (2010). "Virtual
ligand screening of the p300/CBP histone acetyltransferase: identification of a selective
small molecule inhibitor." Chem Biol 17(5): 471-482.
Brooks, H. B., S. Geeganage, S. D. Kahl, C. Montrose, S. Sittampalam, M. C. Smith and
J. R. Weidner (2004). Basics of Enzymatic Assays for HTS. Assay Guidance Manual. G.
S. Sittampalam, N. P. Coussens, H. Nelson et al. Bethesda (MD).
Brownell, J. E., J. Zhou, T. Ranalli, R. Kobayashi, D. G. Edmondson, S. Y. Roth and C.
D. Allis (1996). "Tetrahymena histone acetyltransferase A: a homolog to yeast Gcn5p
linking histone acetylation to gene activation." Cell 84(6): 843-851.
Cao, X. and T. C. Sudhof (2001). "A transcriptionally [correction of transcriptively] active
complex of APP with Fe65 and histone acetyltransferase Tip60." Science 293(5527):
115-120.
Cao, X. and T. C. Sudhof (2004). "Dissection of amyloid-beta precursor proteindependent transcriptional transactivation." J Biol Chem 279(23): 24601-24611.
Cereseto, A., L. Manganaro, M. I. Gutierrez, M. Terreni, A. Fittipaldi, M. Lusic, A.
Marcello and M. Giacca (2005). "Acetylation of HIV-1 integrase by p300 regulates viral
integration." EMBO J 24(17): 3070-3081.
126

Chen, L., T. Wei, X. Si, Q. Wang, Y. Li, Y. Leng, A. Deng, J. Chen, G. Wang, S. Zhu and
J. Kang (2013). "Lysine acetyltransferase GCN5 potentiates the growth of non-small cell
lung cancer via promotion of E2F1, cyclin D1, and cyclin E1 expression." J Biol Chem
288(20): 14510-14521.
Choudhary, C., C. Kumar, F. Gnad, M. L. Nielsen, M. Rehman, T. C. Walther, J. V.
Olsen and M. Mann (2009). "Lysine acetylation targets protein complexes and coregulates major cellular functions." Science 325(5942): 834-840.
Copeland, R. A. (2005). "Evaluation of enzyme inhibitors in drug discovery. A guide for
medicinal chemists and pharmacologists." Methods Biochem Anal 46: 1-265.
Dahlin, J. L., T. Kottom, J. Han, H. Zhou, M. A. Walters, Z. Zhang and A. H. Limper
(2014). "Pneumocystis jirovecii Rtt109, a novel drug target for Pneumocystis pneumonia
in immunosuppressed humans." Antimicrob Agents Chemother 58(7): 3650-3659.
Emsley, P. and K. Cowtan (2004). "Coot: model-building tools for molecular graphics."
Acta Crystallographica Section D-Biological Crystallography 60: 2126-2132.
Falk, H., T. Connor, H. Yang, K. J. Loft, J. L. Alcindor, G. Nikolakopoulos, R. N. Surjadi,
J. D. Bentley, M. K. Hattarki, O. Dolezal, J. M. Murphy, B. J. Monahan, T. S. Peat, T.
Thomas, J. B. Baell, J. P. Parisot and I. P. Street (2011). "An efficient high-throughput
screening method for MYST family acetyltransferases, a new class of epigenetic drug
targets." J Biomol Screen 16(10): 1196-1205.
Feng, B. Y., A. Simeonov, A. Jadhav, K. Babaoglu, J. Inglese, B. K. Shoichet and C. P.
Austin (2007). "A high-throughput screen for aggregation-based inhibition in a large
compound library." J Med Chem 50(10): 2385-2390.
Fraga, M. F., E. Ballestar, A. Villar-Garea, M. Boix-Chornet, J. Espada, G. Schotta, T.
Bonaldi, C. Haydon, S. Ropero, K. Petrie, N. G. Iyer, A. Perez-Rosado, E. Calvo, J. A.
Lopez, A. Cano, M. J. Calasanz, D. Colomer, M. A. Piris, N. Ahn, A. Imhof, C. Caldas, T.
Jenuwein and M. Esteller (2005). "Loss of acetylation at Lys16 and trimethylation at
Lys20 of histone H4 is a common hallmark of human cancer." Nat Genet 37(4): 391-400.
Ghizzoni, M., J. Wu, T. Gao, H. J. Haisma, F. J. Dekker and Y. George Zheng (2012).
"6-alkylsalicylates are selective Tip60 inhibitors and target the acetyl-CoA binding site."
Eur J Med Chem 47(1): 337-344.
He, L., A. Sabet, S. Djedjos, R. Miller, X. Sun, M. A. Hussain, S. Radovick and F. E.
Wondisford (2009). "Metformin and insulin suppress hepatic gluconeogenesis through
phosphorylation of CREB binding protein." Cell 137(4): 635-646.
Herrera, J. E., M. Bergel, X. J. Yang, Y. Nakatani and M. Bustin (1997). "The histone
acetyltransferase activity of human GCN5 and PCAF is stabilized by coenzymes." J Biol
Chem 272(43): 27253-27258.

127

Hobbs, C. A., G. Wei, K. DeFeo, B. Paul, C. S. Hayes and S. K. Gilmour (2006). "Tip60
protein isoforms and altered function in skin and tumors that overexpress ornithine
decarboxylase." Cancer Res 66(16): 8116-8122.
Hou, F. and H. Zou (2005). "Two human orthologues of Eco1/Ctf7 acetyltransferases are
both required for proper sister-chromatid cohesion." Mol Biol Cell 16(8): 3908-3918.
Iizuka, M. and B. Stillman (1999). "Histone acetyltransferase HBO1 interacts with the
ORC1 subunit of the human initiator protein." J Biol Chem 274(33): 23027-23034.
Ivanov, D., A. Schleiffer, F. Eisenhaber, K. Mechtler, C. H. Haering and K. Nasmyth
(2002). "Eco1 is a novel acetyltransferase that can acetylate proteins involved in
cohesion." Curr Biol 12(4): 323-328.
Johnston, P. A., K. M. Soares, S. N. Shinde, C. A. Foster, T. Y. Shun, H. K. Takyi, P.
Wipf and J. S. Lazo (2008). "Development of a 384-well colorimetric assay to quantify
hydrogen peroxide generated by the redox cycling of compounds in the presence of
reducing agents." Assay Drug Dev Technol 6(4): 505-518.
Joseph-McCarthy, D., A. J. Campbell, G. Kern and D. Moustakas (2014). "Fragmentbased lead discovery and design." J Chem Inf Model 54(3): 693-704.
Kabsch, W. (2010). "Xds." Acta Crystallogr D Biol Crystallogr 66(Pt 2): 125-132.
Kadlec, J., E. Hallacli, M. Lipp, H. Holz, J. Sanchez-Weatherby, S. Cusack and A. Akhtar
(2011). "Structural basis for MOF and MSL3 recruitment into the dosage compensation
complex by MSL1." Nat Struct Mol Biol 18(2): 142-149.
Karanam, B., L. Wang, D. Wang, X. Liu, R. Marmorstein, R. Cotter and P. A. Cole
(2007). "Multiple roles for acetylation in the interaction of p300 HAT with ATF-2."
Biochemistry 46(28): 8207-8216.
Kaypee, S., D. Sudarshan, M. K. Shanmugam, D. Mukherjee, G. Sethi and T. K. Kundu
(2016). "Aberrant lysine acetylation in tumorigenesis: Implications in the development of
therapeutics." Pharmacol Ther.
Khanbabaee, K. and T. van Ree (2001). "Tannins: classification and definition." Nat Prod
Rep 18(6): 641-649.
Kinoshita, A., C. M. Whelan, O. Berezovska and B. T. Hyman (2002). "The gamma
secretase-generated carboxyl-terminal domain of the amyloid precursor protein induces
apoptosis via Tip60 in H4 cells." J Biol Chem 277(32): 28530-28536.
Kishimoto, M., T. Kohno, K. Okudela, A. Otsuka, H. Sasaki, C. Tanabe, T. Sakiyama, C.
Hirama, I. Kitabayashi, J. D. Minna, S. Takenoshita and J. Yokota (2005). "Mutations
and deletions of the CBP gene in human lung cancer." Clin Cancer Res 11(2 Pt 1): 512519.

128

Kitabayashi, I., Y. Aikawa, L. A. Nguyen, A. Yokoyama and M. Ohki (2001). "Activation
of AML1-mediated transcription by MOZ and inhibition by the MOZ-CBP fusion protein."
EMBO J 20(24): 7184-7196.
Kleff, S., E. D. Andrulis, C. W. Anderson and R. Sternglanz (1995). "Identification of a
gene encoding a yeast histone H4 acetyltransferase." J Biol Chem 270(42): 2467424677.
Lafon, A., C. S. Chang, E. M. Scott, S. J. Jacobson and L. Pillus (2007). "MYST
opportunities for growth control: yeast genes illuminate human cancer gene functions."
Oncogene 26(37): 5373-5384.
Lau, O. D., T. K. Kundu, R. E. Soccio, S. Ait-Si-Ali, E. M. Khalil, A. Vassilev, A. P.
Wolffe, Y. Nakatani, R. G. Roeder and P. A. Cole (2000). "HATs off: selective synthetic
inhibitors of the histone acetyltransferases p300 and PCAF." Mol Cell 5(3): 589-595.
Li, Y., L. Zhang, T. Liu, C. Chai, Q. Fang, H. Wu, P. A. Agudelo Garcia, Z. Han, S. Zong,
Y. Yu, X. Zhang, M. R. Parthun, J. Chai, R. M. Xu and M. Yang (2014). "Hat2p
recognizes the histone H3 tail to specify the acetylation of the newly synthesized H3/H4
heterodimer by the Hat1p/Hat2p complex." Genes Dev 28(11): 1217-1227.
Lin, C. and Y. A. Yuan (2008). "Structural insights into histone H3 lysine 56 acetylation
by Rtt109." Structure 16(10): 1503-1510.
Lin, Y.-y., J.-y. Lu, J. Zhang, W. Walter, W. Dang, J. Wan, S.-C. Tao, J. Qian, Y. Zhao, J.
D. Boeke, S. L. Berger and H. Zhu (2009). "Protein Acetylation Microarray Reveals that
NuA4 Controls Key Metabolic Target Regulating Gluconeogenesis." Cell 136(6): 10731084.
Lleonart, M., F. Vidal, D. Gallardo, M. Diaz-Fuertes, F. Rojo, M. Cuatrecasas, L. LopezVicente, H. Kondoh, C. Blanco, A. Carnero and S. Ramon y Cajal (2006). "New p53
related genes in human tumors: significant downregulation in colon and lung
carcinomas." Oncol Rep 16(3): 603-608.
Lopes da Rosa, J., V. L. Boyartchuk, L. J. Zhu and P. D. Kaufman (2010). "Histone
acetyltransferase Rtt109 is required for Candida albicans pathogenesis." Proc Natl Acad
Sci U S A 107(4): 1594-1599.
Lu, L., L. Li, X. Lv, X. S. Wu, D. P. Liu and C. C. Liang (2011). "Modulations of hMOF
autoacetylation by SIRT1 regulate hMOF recruitment and activities on the chromatin."
Cell Res 21(8): 1182-1195.
Mantelingu, K., B. A. Reddy, V. Swaminathan, A. H. Kishore, N. B. Siddappa, G. V.
Kumar, G. Nagashankar, N. Natesh, S. Roy, P. P. Sadhale, U. Ranga, C. Narayana and
T. K. Kundu (2007). "Specific inhibition of p300-HAT alters global gene expression and
represses HIV replication." Chem Biol 14(6): 645-657.

129

Mccoy, A. J., R. W. Grosse-Kunstleve, P. D. Adams, M. D. Winn, L. C. Storoni and R. J.
Read (2007). "Phaser crystallographic software." Journal of Applied Crystallography 40:
658-674.
McGovern, S. L., B. T. Helfand, B. Feng and B. K. Shoichet (2003). "A specific
mechanism of nonspecific inhibition." J Med Chem 46(20): 4265-4272.
Mellert, H. S. and S. B. McMahon (2009). "hMOF, a KAT(8) with many lives." Mol Cell
36(2): 174-175.
Miller, R. W. and J. H. Rubinstein (1995). "Tumors in Rubinstein-Taybi syndrome." Am J
Med Genet 56(1): 112-115.
Muraoka, M., M. Konishi, R. Kikuchi-Yanoshita, K. Tanaka, N. Shitara, J. M. Chong, T.
Iwama and M. Miyaki (1996). "p300 gene alterations in colorectal and gastric
carcinomas." Oncogene 12(7): 1565-1569.
Neuwald, A. F. and D. Landsman (1997). "GCN5-related histone N-acetyltransferases
belong to a diverse superfamily that includes the yeast SPT10 protein." Trends Biochem
Sci 22(5): 154-155.
Olia, A. S., K. Barker, C. E. McCullough, H. Y. Tang, D. W. Speicher, J. Qiu, J. LaBaer
and R. Marmorstein (2015). "Nonenzymatic Protein Acetylation Detected by NAPPA
Protein Arrays." ACS Chem Biol.
Otwinowski, Z. and W. Minor (1997). "Processing of X-ray diffraction data collected in
oscillation mode." Macromolecular Crystallography, Pt A 276: 307-326.
Pantoliano, M. W., A. W. Rhind and F. R. Salemme (2000). Microplate thermal shift
assay for ligand development and multi-variable protein chemistry optimization, Google
Patents.
Parthun, M. R., J. Widom and D. E. Gottschling (1996). "The major cytoplasmic histone
acetyltransferase in yeast: links to chromatin replication and histone metabolism." Cell
87(1): 85-94.
Patel, D., J. D. Bauman and E. Arnold (2014). "Advantages of crystallographic fragment
screening: functional and mechanistic insights from a powerful platform for efficient drug
discovery." Prog Biophys Mol Biol 116(2-3): 92-100.
Qin, Y. R., L. Fu, P. C. Sham, D. L. Kwong, C. L. Zhu, K. K. Chu, Y. Li and X. Y. Guan
(2008). "Single-nucleotide polymorphism-mass array reveals commonly deleted regions
at 3p22 and 3p14.2 associate with poor clinical outcome in esophageal squamous cell
carcinoma." Int J Cancer 123(4): 826-830.
Rebel, V. I., A. L. Kung, E. A. Tanner, H. Yang, R. T. Bronson and D. M. Livingston
(2002). "Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell
self-renewal." Proc Natl Acad Sci U S A 99(23): 14789-14794.
130

Rubinstein, J. H. and H. Taybi (1963). "Broad thumbs and toes and facial abnormalities.
A possible mental retardation syndrome." Am J Dis Child 105: 588-608.
Santos-Rosa, H., E. Valls, T. Kouzarides and M. Martinez-Balbas (2003). "Mechanisms
of P/CAF auto-acetylation." Nucleic Acids Res 31(15): 4285-4292.
Sapountzi, V. and J. Cote (2011). "MYST-family histone acetyltransferases: beyond
chromatin." Cell Mol Life Sci 68(7): 1147-1156.
Seiden-Long, I. M., K. R. Brown, W. Shih, D. A. Wigle, N. Radulovich, I. Jurisica and M.
S. Tsao (2006). "Transcriptional targets of hepatocyte growth factor signaling and Ki-ras
oncogene activation in colorectal cancer." Oncogene 25(1): 91-102.
Shida, T., J. G. Cueva, Z. Xu, M. B. Goodman and M. V. Nachury (2010). "The major
alpha-tubulin K40 acetyltransferase alphaTAT1 promotes rapid ciliogenesis and efficient
mechanosensation." Proc Natl Acad Sci U S A 107(50): 21517-21522.
Smith, K. T. and J. L. Workman (2009). "Introducing the acetylome." Nat Biotechnol
27(10): 917-919.
Spange, S., T. Wagner, T. Heinzel and O. H. Kramer (2009). "Acetylation of non-histone
proteins modulates cellular signalling at multiple levels." Int J Biochem Cell Biol 41(1):
185-198.
Stavropoulos, P., V. Nagy, G. Blobel and A. Hoelz (2008). "Molecular basis for the
autoregulation of the protein acetyl transferase Rtt109." Proc Natl Acad Sci U S A
105(34): 12236-12241.
Sun, B., S. Guo, Q. Tang, C. Li, R. Zeng, Z. Xiong, C. Zhong and J. Ding (2011).
"Regulation of the histone acetyltransferase activity of hMOF via autoacetylation of
Lys274." Cell Res 21(8): 1262-1266.
Sun, C., M. Wang, X. Liu, L. Luo, K. Li, S. Zhang, Y. Wang, Y. Yang, F. Ding and X. Gu
(2014). "PCAF improves glucose homeostasis by suppressing the gluconeogenic activity
of PGC-1alpha." Cell Rep 9(6): 2250-2262.
Sunde, J. S., H. Donninger, K. Wu, M. E. Johnson, R. G. Pestell, G. S. Rose, S. C. Mok,
J. Brady, T. Bonome and M. J. Birrer (2006). "Expression profiling identifies altered
expression of genes that contribute to the inhibition of transforming growth factor-beta
signaling in ovarian cancer." Cancer Res 66(17): 8404-8412.
Tang, Y., K. Meeth, E. Jiang, C. Luo and R. Marmorstein (2008). "Structure of Vps75
and implications for histone chaperone function." Proc Natl Acad Sci U S A 105(34):
12206-12211.
Terreni, M., P. Valentini, V. Liverani, M. I. Gutierrez, C. Di Primio, A. Di Fenza, V.
Tozzini, A. Allouch, A. Albanese, M. Giacca and A. Cereseto (2010). "GCN5-dependent
acetylation of HIV-1 integrase enhances viral integration." Retrovirology 7: 18.
131

Thompson, P. R., D. Wang, L. Wang, M. Fulco, N. Pediconi, D. Zhang, W. An, Q. Ge, R.
G. Roeder, J. Wong, M. Levrero, V. Sartorelli, R. J. Cotter and P. A. Cole (2004).
"Regulation of the p300 HAT domain via a novel activation loop." Nat Struct Mol Biol
11(4): 308-315.
Toth, M., I. M. Boros and E. Balint (2012). "Elevated level of lysine 9-acetylated histone
H3 at the MDR1 promoter in multidrug-resistant cells." Cancer Sci 103(4): 659-669.
Vetting, M. W., S. d. C. LP, M. Yu, S. S. Hegde, S. Magnet, S. L. Roderick and J. S.
Blanchard (2005). "Structure and functions of the GNAT superfamily of
acetyltransferases." Arch Biochem Biophys 433(1): 212-226.
Wang, H., K. Liu, B. A. Fang, H. Wu, F. Li, X. Xiang, W. Tang, G. Zhao, L. Lin, S. Bao
and Q. Xie (2015). "Identification of acetyltransferase genes (HAT1 and KAT8)
regulating HBV replication by RNAi screening." Cell Biosci 5: 66.
Wang, L., Y. Tang, P. A. Cole and R. Marmorstein (2008). "Structure and chemistry of
the p300/CBP and Rtt109 histone acetyltransferases: implications for histone
acetyltransferase evolution and function." Curr Opin Struct Biol 18(6): 741-747.
Williams, B. C., C. M. Garrett-Engele, Z. Li, E. V. Williams, E. D. Rosenman and M. L.
Goldberg (2003). "Two putative acetyltransferases, san and deco, are required for
establishing sister chromatid cohesion in Drosophila." Curr Biol 13(23): 2025-2036.
Williams, K. P. and J. E. Scott (2009). "Enzyme assay design for high-throughput
screening." Methods Mol Biol 565: 107-126.
Wu, J., J. Wang, M. Li, Y. Yang, B. Wang and Y. G. Zheng (2011). "Small molecule
inhibitors of histone acetyltransferase Tip60." Bioorg Chem 39(1): 53-58.
Wu, J., N. Xie, Z. Wu, Y. Zhang and Y. G. Zheng (2009). "Bisubstrate Inhibitors of the
MYST HATs Esa1 and Tip60." Bioorg Med Chem 17(3): 1381-1386.
Xue, L., J. Hou, Q. Wang, L. Yao, S. Xu and D. Ge (2014). "RNAi screening identifies
HAT1 as a potential drug target in esophageal squamous cell carcinoma." Int J Clin Exp
Pathol 7(7): 3898-3907.
Yan, Y., N. A. Barlev, R. H. Haley, S. L. Berger and R. Marmorstein (2000). "Crystal
structure of yeast Esa1 suggests a unified mechanism for catalysis and substrate
binding by histone acetyltransferases." Mol Cell 6(5): 1195-1205.
Yan, Y., S. Harper, D. W. Speicher and R. Marmorstein (2002). "The catalytic
mechanism of the ESA1 histone acetyltransferase involves a self-acetylated
intermediate." Nat Struct Biol 9(11): 862-869.
Yang, C., J. Wu and Y. G. Zheng (2012). "Function of the active site lysine
autoacetylation in Tip60 catalysis." PLoS One 7(3): e32886.

132

Yang, X. J. (2004). "The diverse superfamily of lysine acetyltransferases and their roles
in leukemia and other diseases." Nucleic Acids Res 32(3): 959-976.
Yang, X. J., V. V. Ogryzko, J. Nishikawa, B. H. Howard and Y. Nakatani (1996). "A
p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A." Nature
382(6589): 319-324.
Ying, M. Z., J. J. Wang, D. W. Li, G. Yu, X. Wang, J. Pan, Y. Chen and M. X. He (2010).
"The p300/CBP associated factor is frequently downregulated in intestinal-type gastric
carcinoma and constitutes a biomarker for clinical outcome." Cancer Biol Ther 9(4): 312320.
Yuan, H. and R. Marmorstein (2013). "Histone acetyltransferases: Rising ancient
counterparts to protein kinases." Biopolymers 99(2): 98-111.
Yuan, H., D. Rossetto, H. Mellert, W. Dang, M. Srinivasan, J. Johnson, S. Hodawadekar,
E. C. Ding, K. Speicher, N. Abshiru, R. Perry, J. Wu, C. Yang, Y. G. Zheng, D. W.
Speicher, P. Thibault, A. Verreault, F. B. Johnson, S. L. Berger, R. Sternglanz, S. B.
McMahon, J. Cote and R. Marmorstein (2012). "MYST protein acetyltransferase activity
requires active site lysine autoacetylation." EMBO J 31(1): 58-70.
Zhang, J., R. Sprung, J. Pei, X. Tan, S. Kim, H. Zhu, C. F. Liu, N. V. Grishin and Y. Zhao
(2009). "Lysine acetylation is a highly abundant and evolutionarily conserved
modification in Escherichia coli." Mol Cell Proteomics 8(2): 215-225.
Zhang, J. H., T. D. Chung and K. R. Oldenburg (1999). "A Simple Statistical Parameter
for Use in Evaluation and Validation of High Throughput Screening Assays." J Biomol
Screen 4(2): 67-73.
Zheng, Y., K. Balasubramanyam, M. Cebrat, D. Buck, F. Guidez, A. Zelent, R. M. Alani
and P. A. Cole (2005). "Synthesis and evaluation of a potent and selective cellpermeable p300 histone acetyltransferase inhibitor." J Am Chem Soc 127(49): 1718217183.

133

